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Individuals who are overweight or obese are at increased risk for cancer.
However, the mechanistic link between obesity and cancer is poorly defined. Adipose
tissue produces hormones and pro-inflammatory cytokines with mitogenic properties.
Many of these hormones and cytokines are altered in obese individuals and may lead to
disruption of the normal balance between cell proliferation, differentiation, and apoptosis.
Thus, the objective of this study was to determine how adipocyte-derived factors regulate
the expression of genes that contribute to cell proliferation and migration. To compare
immediate early gene (cell proliferation) and epithelial-mesenchymal transition (cell
migration) gene expression between untreated and treated cells, HeLa cells were exposed
to IGF-1 (100ng/ml), leptin (100ng/ml), TNFα (10ng/ml), or IL-6 (10ng/ml) and QPCR
analyses were carried out. Immediate early gene expression was regulated by all four
hormones. Specifically, IGF-1 increased Jun, Fos, and Il-8; leptin increased Jun and Il-6;
IL-6 increased Fos, Il-6, and Il-8; and TNFα increased Jun, Fos, Il-6, and Il-8 mRNA
abundance. Genes that regulate the epithelial-mesenchymal transition were also

regulated by IGF-1, IL-6, and TNF. Specifically, IGF-1 increased Snail1 and Snail2; IL6 increased Snail1; and TNF increased Jag1 mRNAs. Interestingly, the expression of
Snail1, Snail2, JUN, and FOS was increased in the uterus of age-matched obese
compared to normal-weight mice. Western blot analyses demonstrated that these changes
in mRNA abundance were associated with increased phosphorylation of Akt, Erk1/2, Jnk,
and Stat3 in treated compared to untreated cells suggesting that these signaling factors
play a role in the regulation of immediate early and epithelial-mesenchymal transition
gene expression. These studies demonstrate for the first time a mechanistic link between
factors produced and secreted by adipocytes and the expression of genes associated with
cell transformation, proliferation, and migration. These cell functions play an important
role in tumorigenesis and therefore changes in their expression may provide a plausible
mechanism for obesity-dependent increases in a myriad of cancers.
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CHAPTER 1
LITERATURE REVIEW
Clinical correlations between BMI and Cancer Risks
Obesity is a worldwide epidemic and health threat which arose as an unintended
consequence of economic, social, and technological advances. Obesity is defined based
on the body mass index (BMI) measurement which is calculated by the following
formula: BMI = weight (kg)/height squared (m2). BMI provides an accurate measurement
to determine whether a patient is obese or overweight (1, 2) . A person is defined as
overweight if BMI is greater than 25.0 but less than 29.9 and as obese if BMI is greater
than 30.0. Since 1980, over one billion adults have been classified as overweight or
obese (3, 4). Likewise, the CDC indicated that in 2007-2008 (5), approximately 72.5
million adults in the United States were obese (CDC, unpublished data, 2010).
Unfortunately, obesity is growing at an exponential rate in both developed and
developing countries, and is even expanding among youth. In the United States, the ratio
of people classified as obese is more than one-third of all adults.
Patients who are obese experience several health problems which impact the
quality of life. Specifically, obese adults are at increased risk for development of
coronary heart disease, hypertension, stroke, and type 2 diabetes. In addition, overweight
and obesity is associated with certain types of cancer including kidney, breast
(postmenopausal), endometrium, colon, gallbladder, ovary, pancreas and esophagus (6),
(7). For example, after menopause, the risk for breast cancer is 1.5 times greater in an
obese compared to an age-matched, normal-weight woman (8, 9). Likewise, Bergstrom et
al. reported that obese women have up to a four-fold increased risk for endometrial
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cancer than normal-weight women (10). In fact, approximately 40 percent of endometrial
cancer patients are overweight or obese. Increased cancer risk due to obesity also impacts
men. For example, there is a weak positive relationship between male BMI and the risk
for colon cancer (11).
Despite the plethora of data linking obesity to increased cancer incidence, the
mechanism of obesity-induced cancer development and progression is still unclear.
Furthermore, it is likely that the specific mechanisms differ depending on cancer type.
Adipose tissue is an endocrine organ and therefore, one possible mechanism includes
chronic exposure to altered hormone and adipocytokine profiles associated with obesity
(12, 13). Excess adipose tissue is characterized by altered endocrine hormone synthesis
and increased macrophage infiltration which is an important source of pro-inflammatory
cytokines produced by this tissue. Specifically, adipose tissue produces interleukin 6 (IL6), tumor necrosis factor alpha (TNF ), adiponectin, inhibitor of NF- B kinase b (IKKb),
macrophage migration inhibitory factor, nerve growth factor, vascular endothelial growth
factor (VEGF), plasminogen activator inhibitor 1 and haptoglobin, which act at both the
local (autocrine/paracrine) and systemic (endocrine) level (14-16). Furthermore, chronic,
excess adipose tissue alters the synthesis of endocrine hormones including sex steroids,
insulin, and insulin-like growth factor (IGF).
Hormone Profiles and Obesity
IGF System: Insulin-like growth factors (IGFs) are polypeptide hormones which
are mainly produced by liver but are also synthesized by various other tissues including
the ovary and uterus. The IGF family consists of two ligands, IGF-1 and IGF-2, which
both share approximately 50% structural homology to insulin (17). The synthesis of IGF-

3

1 in the liver is stimulated by growth hormone (GH) and represents a primary mediator of
GH action (18). Conversely, the synthesis of IGF-2 is GH-independent. Both IGF-1 and
IGF-2 play an important role in the regulation of cell growth and survival via regulation
of mitogenesis, differentiation, and apoptosis (19, 20). Thus, IGF-1 and IGF-2 have
growth-promoting effects on almost every cell in the body, especially skeletal muscle,
cartilage, bone, liver, kidney, nerves, skin, hematopoietic cell, and lungs, although the
actions of IGF-2 are likely restricted to fetal development in mammals (19, 20).
The actions of the IGF ligands are mediated by one of three receptors, the IGF-1
receptor, the IGF-2 receptor and the insulin receptor. The IGF-1 receptor (IGF1R) is a
tyrosine kinase receptor which includes two α and two β subunits that have 60%,
sequence homology to the insulin receptor (Fig. 1.1) (19). Both IGF-1 and IGF-2 bind
with high affinity to the IGF1R which is expressed in all tissues except the liver.
Activation of the IGF1R promotes cell survival, cell proliferation, protein synthesis, and
DNA and RNA synthesis (19, 20). The IGF-2 receptor (IGF2R) is monomeric and
structurally identical to the mannose 6 phosphate receptor (Fig. 1.1). IGF-2 binds to the
IGF2R with much higher affinity than IGF-1. Furthermore, the IGF2R does not have
tyrosine kinase activity and acts as a decoy receptor which promotes degradation and
therefore clearance of IGF2 from the circulation (19). In addition to these two IGF
receptors, IGF-1 and IGF-2 are able to bind to the insulin receptor, although at a much
lower affinity (i.e. 100-fold less than insulin). However, studies have demonstrated that
high concentrations of IGF-1 can induce insulin receptor dependent signaling (17, 21).
The ability of IGFs to bind to these receptors is also dependent of the expression of
binding proteins. There are 6 binding proteins (IGFBP1 – IGFBP6) which interact with
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both IGF-1 and IGF-2 and inhibit interaction of ligands with receptors as well as prolong
ligand half-life (19). Interestingly, IGFBP-1, IGFBP-3, and IGFBP-5 can also potentiate
IGF activity.
The effect of an obese phenotype on the GH-IGF axis remains unclear with
conflicting results documented in the literature. The concentration of serum total IGF
shows little or nodiurnal variation by Baxter (22). However, Frystyk et al. showed that
obesity is associated with a decrease in GH. The level of GH secretion is diminished in
obesity and reversible with weight loss. However, obesity-dependent decreased GH level
is not always correlated with decreased IGF-1 level in obesity (23, 24). In obesity, free
IGF-1 levels are actually increased in obese men and to a lesser extent in woman (Fig. 1.2)
(25). In addition, individuals with low IGF-1 level tend to more easily weight gain and
obesity (23, 24, 26). Using a mouse model of obesity (Lethal Yellow; LY), our lab has
demonstrated changes in total circulating IGF-1 levels during the development of obesity
(Fig. 1.3) (Mack and Wood, unpublished data). Specifically, at 6 weeks of age, prior to
the onset of obesity, circulating levels of IGF-1 were significantly increased (P < 0.01) in
LY female mice compared to age-matched female C57BL/6 (B6) control. These
increased levels decreased in LY mice returning to comparable levels to B6 mice by 12
weeks of age (Mack and Wood, unpublished data). Studies have also shown an
association between circulating IGF-1 levels and bady fat in domestic livestock. For
example, the development of lower perirenal fat observed in low body weight involves an
alteration of the IGF system as shown in the liver and skeletal muscle of growth-retarded
fetuses and neonates in pig (27, 28). Furthermore, these changes in IGF-1 concentrations
have an effect on reproductive performance in beef cattle (29).
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The relationship between IGF1 and neoplasia has drawn attention for several
years. In 1987, Tricoli reported that increased IGF-1 mRNA is increased 3 to 5 fold in
human colon cancer compared to the control (30). When IGF-1 was added to serum free
media with the concentration of 10µg/L, the growth of mouse colon adenocarcinoma
increased (31). Moreover, a high IGF-1/IGFBP-3 ratio would increase the risk of colon
cancer development suggesting that IGF-1 stimulates the growth of colon cancer cells
(32). In addition, IGF-1 has mitogenic effect on the St16, St42 and MKN45 gastric
cancer cell lines , as well as human pancreatic cell line such as ASPC-1and COLO357
(33, 34). In lung cancer cells, there is increased IGF-1 concentration in the cancerous
tissue, and IGF-1 stimulates the growth of the lung cancer cell line CALU-6 inducing a
52% increase (35). In breast cancer cells, IGF-I and IGF-II are potent mitogens, and
combine with estrogen to stimulate cell growth in a synergistic manner (36). Ferlanetto
reported that IGF-1 stimulated DNA synthesis in multiple breast cancer cell lines
including MCF-7, T47D, MDA-MB-23 and HBL-100 (36). Clinical studies also
demonstrated that there is elevated IGF-1 levels in breast cancer patients (37). Finally,
men with elevated IGF-1 concentrations are at increased risk for developing prostate
cancer (37).
Taken together, these data provide evidence that the IGF system is involved in
cancer growth. One mechanism of IGF-dependent tumorigenesis may be that IGFs are
mitogenic and anti-apoptotic peptides that enhance the proliferation and reduce the death
of various cell types. Angiogenesis also plays a critical role in the development of
cancers. IGF-I is able to activate sphingosine kinase (SphK) in human endothelial cells,
leading to sphingosine-1-phosphate (S1P) formation. Insulin-like growth factor binding
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protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. There
is also evidence that the increase of breast tumor angiogenesis depends on interactions of
M6P/IGF-IIR with mannose 6-phosphate-containing proteins (38). IGFs also play
important roles in cancer metastasis. Recent studies showed that numerous predictive
markers of colorectal carcinoma metastasis include IGF-II, TGF-a, EGFR, matrix
metalloproteinase (MMP)-2, vascular endothelial growth factor (VEGF) (17). In
melanoma patients, there is a significant correlation between high IGF-IR level and the
risk of liver metastasis. Furthermore, overexpression of IGF-IR in the primary gastric
tumor is correlated with increased lymph node metastasis (39-41). Finally, high levels of
IGF-1 and IGF-2 enhance choriocarcinoma cell adhesion and invasion (39-41). Taken
together, these collective studies provides strong evidence that the IGF system is
involved in human cancer progression and emphasizes the importance of targeting IGF
signaling and developing drugs capable of inhibiting IGF signaling as anticancer therapy
(42, 43).
Leptin: Leptin is a peptide hormone of 16kDa and 167 amino acids. It is one of
the most important adipose derived hormones, which plays a key role in regulating
energy intake and energy expenditure, and regulating appetite and metabolism. Leptin is
the product of the "obesity" (ob) gene which was discovered in 1994 by Zhang and is
located on chromosome 7 in humans (44). Leptin is expressed primarily in the adipocytes
of white adipose tissue and, at lower levels, in gastric epithelium and placenta (45, 46).
Interestingly, like other endocrine hormones, leptin levels fluctuate in a diurnal and
pulsatile fashion. Circulating leptin levels reach maximum after midnight, whereas they
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are lowest around noon. There is also evidence that glucocorticoids up-regulate leptin
levels in the human (47, 48)
Leptin interacts with six types of receptors including Ob-Ra–Ob-Rf, or LepRaLepRf. Leptin receptors have two isoforms, long and short, with the short form generally
located in peripheral tissue including the liver, kidney, heart, skeletal muscles, and the
pancreas, and the long form mainly expressed in the hypothalamus. The main function of
leptin in the hypothalamic neurons is to regulate appetite control. Specifically, leptin
reduces food intake by upregulating anorexigenic (appetite-reducing) neuropeptides, such
as -melanocyte-stimulating hormone, and downregulating orexigenic factors, primarily
neuropeptide Y (NPY) in the hypothalamus (47, 48).
In obese individuals circulating leptin levels are generally higher than in normalweight individuals. These higher leptin concentrations in the serum of obese individuals
is associated with both increased fat mass and increased leptin release from larger
adipocytes (49). Unlike IGF-1, there is a significant correlation between leptin levels and
percent body fat in both sexes. However, the absolute peak leptin level is higher in
women than in men (49, 50). In ruminant animals, leptin level in serum fluctuates with
body condition in a similar pattern as humans. Furthermore, leptin levels are associated
with different nutritional conditions in cattle. For example, plasma leptin concentration
measured 4 h after meal is positively related to feed intake and to plasma 3-OH-butyrate,
and negatively related to plasma NEFA. Leptin concentrations decrease after meal intake
in well-fed cows but increase in underfed cows (51, 52). In our mouse model of obesity,
leptin is significantly increased (P < 0.001) in LY compared to B6 females at 12 and 24
weeks of age (Fig 1.3; Mack and Wood, unpublished data). Based on these data, leptin
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was originally considered a good target for treating obesity by the scientific and clinical
communities. However, the complexity of the leptin axis and the development of leptin
resistance make leptin a poor target for obesity therapy.
Given that obesity is risk factor in various cancers and leptin plays a significant
role in obesity, the relationship between leptin levels and cancer risk has been seriously
considered. Several reports demonstrate a role for leptin in the pathogenesis of a series of
different forms of cancers, including cancers of the male and female reproductive tract
(breast, endometrial, ovarian and prostate cancer), cancers of the gastrointestinal tract
(esophagus, gastric and colon cancer) and leukemias (49). In breast cancer, leptin
increases cell proliferation and cell transformation (anchorage-independent growth). One
mechanism for these cellular changes is leptin-dependent increases in AP-1 activation
which results in increased cdk2, cyclinD1 and P450 aromatase expression and
hyperphosphorylation of the retinoblastoma (Rb) protein. Furthermore, it induces c-myc
expression and stabilizes ERα expression (53, 54). In colorectal cancer, leptin increases
cell growth through the ERK1/2 pathway, increases cell invasion via an PI-3K, Rho- and
Rac-dependent pathways, and reduces cell apoptosis via stimulation of NF-kB signaling
(55). In prostate cancer, leptin increases cell proliferation and suppresses apoptosis (56).
In pancreatic cancer, leptin decreases cell proliferation through stimulation of STAT3 and
STAT5b phosphorylation (57). In ovarian and lung cancer, leptin increases proliferation
through the ERK1/2 pathway (58, 59).
IL-6 and TNF : Adipose tissue is not only the source of endocrine hormones, but
is also infiltrated with macrophages which are an important source of inflammatory
factors. In fact, excess adipose tissue associated with obesity is recognized as a chronic
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inflammatory organ characterized by high expression of interleukin 6 (IL-6) , tumor
necrosis factor alpha (TNF , inhibitor of NF- B kinase b (IKKb), macrophage
migration inhibitory factor, nerve growth factor, vascular endothelial growth factor,
plasminogen activator inhibitor 1 and haptoglobin; increased acute-phase reactants, and
activation of inflammatory signaling pathways (15, 16). For example, adipose tissue is a
significant source of circulating TNF

in most rodent models of obesity as well as

human cases of obesity (60, 61). IL-6 is also produced by human adipose tissue and its
circulating levels increase with the increased value of BMI (62, 63).
Interleukin 6 and TNF are multifunctional cytokines that are traditionally
involved in the regulation of the immune response, hematopoiesis, and inflammation.
Interleukin-6 is secreted by T cells and macrophages in response to trauma and mainly
acts as a B cell differentiation factor. Interleukin-6 binds to the sIL-6 receptor (gp80,
present either on the cell surface or in solution) resulting in dimerization of gp80 and the
transmembrane gp130 and the activation of Janus kinase (JAK)(64). Tumor necrosis
factor a belongs to a superfamily of ligands which regulate the establishment of
multicellular structures such as lymphoid organs, hair follicles, bone, and lactating
mammary gland (65). Upon stimulation, macrophages produce TNF which is a 26-kDa
transmembrane protein that is cleaved into a 17-kDa biologically active protein.
Biologically active TNF binds to one of two receptors, 55-kd (TNFR I) or 75-kd (TNFR
II), which are found on most cells. The interaction of biologically active TNF with
these receptors results in multiple cellular responses including apoptosis (most cells), cell
proliferation (lymphocytes), bone resorption, and insulin resistance (Fig. 1.4) (66).

10

Cytokines are known to have both tumor-promoting and inhibitory effects with
these opposing effects dependent on their relative concentrations and the presence of
other factors (67). Furthermore, inflammation is recognized to play important roles in the
pathogenesis of many types of malignancies. Given the ability of adipose cells to produce
cytokines especially during obesity, there could be an association between the proinflammatory cytokine produced by adipose cells and the increased risk of cancer in
obesity. Indeed, elevated circulating IL-6 levels have been reported in breast cancer
patients indicating that IL-6 levels may represent an early marker of breast tumors (67,
68). In addition, Grivennikov and Bollrath have demonstrated the contribution of
interleukin-6 and its downstream effector STAT3 on colitis-associated colon cancer (69,
70). Conversely, TNF generally inhibits tumorigenesis and viral replication. Recently,
TNF has been used as a regional treatment of locally advanced soft tissue sarcomas and
metastatic melanomas and other tumors (71). Together with chemotherapeutic drugs,
TNF shows a synergistic antitumor effect (72). However, TNF-α alone induced only a
mild central necrosis with no objective tumor response observed. In rat models,
chemotherapeutic drugs with TNF-α improved the accumulation of selectively tumor up
to 3 to 6 fold (71, 72). In addition, to these roles of IL-6 and TNF , other bioactive
peptides produced the adipose cell promote angiogenesis associated with metastasis
including vascular endothelial growth factor, hepatocyte growth factor, and heparinbinding epidermal growth factor-like growth factor (68).
Signaling Pathways Regulated by Adiopocytokines
The interaction of adipocytokine ligands with their receptors stimulates multiple
signal transduction pathways. Figure 1.5 shows the complex signaling network
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(including cross-talk between pathways) that functions downstream of the insulin
receptor (IR), the IGF-1 receptor, TNFα receptor, IL-6 receptor and leptin receptor (73).
IGF-1 dependent signaling: When the IGF-1R heterotetramer is activated, the
IRS-1 complex is recruited and phosphorylated, resulting in several signal transduction
cascades to be activated including the phosphotidylinositol-3 kinase (PI3K)/Akt pathway
(Fig. 1.5). Specifically, the lipid products of the PI3-kinase activates a cascade of PI (3, 4,
5)-phosphate (PIP3)-dependent serine/threonine kinases including PDK1. Substrates of
this kinase include PKC isoforms, the serum and glucocorticoid-inducible kinase SGK
and the product of the Akt proto-oncogene. The activation of Akt is an important and
central mediator of IGF-1action on glucose metabolism, cell proliferation and
differentiation, and protein synthesis. In addition to Akt, IGF-1 activation of PI3K can
stimulate c-jun N-terminal kinase (JNK/SAPK) resulting in increased activity of the AP-1
transcription factors (74). For example, Poulaki et al demonstrated that systemic
inhibition of IGF-I signaling with a receptor-neutralizing antibody, or with inhibitors of
PI-3 kinase (PI-3K), c-Jun kinase (JNK), or Akt suppressed retinal Akt, JNK and AP-1
activity. In addition, intravenous administration of IGF-I increased retinal Akt, JNK and
AP-1 activity (74). One mechanism that low IGF-I decreases cancer is that reduced
circulating IGF-I level attenuates activation of Akt and mTOR signaling pathways (73,
75).
Leptin- and IL-6 dependent signaling: Leptin interaction with its
receptors including Ob-Ra–Ob-Rf, or LepRa-LepRf activates the Jak-Stat and mitogen
activated protein kinase (MAPK) signal transduction pathways (73, 76)(77). Mostly,
Leptin binding to the extracellular domain of the long form of the leptin receptor ( LRb)
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which is crucial for leptin action and mainly expressed at basomedial hypothalamus, then
activates the JAK2 tyrosine kinase which associates with LRb via the Box 1 motif and
intracellular amino acids 31–36 of LRb (78). The long form of the receptor is crucial for
leptin action and mainly expressed at basomedial hypothalamus (79). Short form may
relate to leptin across the blood-brain barrier. The three primary intracellular signaling
pathways emanate from LRb, including JAK2-Tyr 1138-stat3 pathway, Tyr 985 - SHP2 ERK pathway and JAK2 tyrosine phosphorylation sites (78). Activation of JAK2 results
in interaction with a conserved SH2 domain containing protein and phosphorylation and
dimerization of STATs (Fig.1.5) (73). Suppressors of cytokine signaling (SOCS) are
recently identified inhibitors of the Janus kinase (JAK)/signal transducers and activators
of transcription (STAT) pathway (79). Increase in SOCS mRNA is observed when cells
are exposed to a wide range of cytokines or growth factors , such as IL-4, IL-6, GH,
Leptin (80). In fact, the phosphorylated STAT dimer translocates to the nucleus to
activate target genes and SOCS transcription. SOCS-1 and SOCS-3 inhibit cytokine
signaling in a feedback manner by inhibiting JAK or by inhibiting the activated receptor
complex (79).
IL-6 interaction with its receptor also activates the JAK/STAT signaling pathway.
Specifically, IL-6 binds to -receptor subunits of IL-6R (gp 80) which are not involved in
the intracellular signal-transduction cascade. After ligand binding, the cytokine and gp 80
complex are able to efficiently dimerize with gp 130 which is the signal-transducing
receptor component (81, 82), activate JAK and recruit STAT family members (Figure
1.6)(64). Activation of JAK also results in the recruitment of SH2 domain protein, and
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subsequently increased activity of the mitogen-activated protein kinase (MAPK) cascade.
Thus, MAPK cascade is another important pathway stimulated by IL-6 (73, 83).
TNFα dependent signaling: TNFα exerts its biological action through activation
of TNFRI and II which in turn activate the extracellular signal-regulated kinase (ERK1/2), p38 mitogen-activated protein kinase (p38 MAPK), phosphoinositide 3-kinase
(PI3K)/Akt and nuclear factor-κB (NF-κB) pathways. TNFRI initiates the majority of
TNF's function. The binding of TNF to TNF-R1 results in the activation of two major
transcription factors, nuclear factor κB (NF-κB) and c-Jun. which is responsible for the
inducible expression of genes important for diverse biological processes, including cell
growth and death, development, oncogenesis, and immune, inflammatory, and stress
responses (66). The chemical inhibitor LY294002 which blocks PI3K activity inhibits
TNFα-induced Akt and ERK phosphorylation. Likewise, the IKK-2 inhibitor IMD-0354
readily prevents TNFα-induced IκB-α phosphorylation and degradation, and thus
activates NFkB activation. In addition, TNFα is able to induce IL-6 expression via
TNFRI, which is dependent on p38 MAPK. Activation of IL-6 mRNA expression by
TNF-α, can also be regulated by JNK via PI3K/Akt/NF-kappaB axis (73, 84). Tumor
necrosis factor receptor-associated factors (TRAFS) are adaptor proteins that couple the
tumor necrosis factor receptor family to signaling pathways. TRAF2, TRAF5 and
TRAF6 have been demonstrated to mediate activation of NF-kB and JNK, which is
important pathway of TNFa (85).

Transcription Factors activated by Adipocytokine Signaling
AP-1 transcription factors: According to Liu's report, IGF-1 also activated the
AP-1 (86). AP-1 converts extracellular signals into cell and make changes of expression
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of specific target genes which harbour AP-1 binding site(s) in their promoter or enhancer
regions. The family of AP-1 transcription factors includes Fos, Jun and ATF families of
proteins (86-88). Normally, these AP-1 factors bind to the12-O-tetradecanoylphorbol-13acetate (TPA) response elements (5′-TGAG/CTCA-3′) or the cAMP response elements
(CRE,5′-TGACGTCA-3′)(86). AP-1 activity is regulated by interactions with other
transcriptional regulators and mediated by upstream kinases which link AP-1 to various
signal pathways including MAPK and JNK (86). AP-1 transcription factors are involved
in a large variety of biological processes such as cell differentiation, proliferation,
apoptosis and oncogenic transformation. For example, Jochum et al. show that c-Jun
binds to the promoter of the P53 and cyclin D1, and then inhibit the p53 gene expression
and stimulate the cycline D1 gene expression during mouse development and in a
tumorigenesis model (Fig. 1.7). C-Fos and FosB also binds to the promoter of the
cyclinD1 and stimulate the gene expression of cyclinD1. JunD can bind to the promoter
of Ras and inhibit the gene expression of Ras, while Jun B binds to the promoter of p16
and stimulates the gene expression of p16 (86). AP-1 transcription factors play important
role in cell differentiation, proliferation, apoptosis and oncogenic transformation.
FOXO transcription factors: In addition to AP-1, several other transcription
factor families are the target of signaling pathways activated by adipocytokines including
FOXO family, NF B family, and Stat family. FOXO (Forkhead box o) transcription
factors play crucial roles in cell growth, proliferation, differentition, metabolism and
stress tolerance. FOXO protein sequence contains 80 to 100 amino acids, which form a
forkhead motif that looks like butterfly in loops and is also called the winged helix motif
that binds to DNA. They belong to helix-turn-helix class of proteins. Four members of
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FOXO family have been discovered. They are FOXO1, FOXO3, FOXO4 and FOXO6
(89, 90). FOXO activity is modified post-translationally due to phosphorylation,
acetylation and ubiquitination. For example, Akt/PKB signaling inhibits FOXO activity
through phosphorylation which causes them to be translocated out of the nucleus (91).
FOXO1 is able to interact with TSC2, androgen receptor, estrogen receptor alpha, and
CREB binding protein (92, 93). FOXO3 functions as a trigger for apoptosis through
activation of Bim and PUMA, or down-regulation of anti-apoptotic proteins FLIP (94).
FOXO3 is known as a tumour suppressor, and inhibition of FOXO3 tends to enhance
tumorigenesis (95).
NF- B transcription factors: NF-κB is a protein complex of transcription factors,
with the name nuclear factor kappa-light-chain-enhancer of activated B cells. NF-κB
family consists of 5 members: RelA, RelB, c-Rel NF-κB1 and NF-κB2, which all contain
a Rel domain in their N-terminus. The NF-κB1 and NF-κB2 proteins are derived from
precursor proteins p105 and p100 respectively, through selective degradation of Cterminal ankyrin repeat region by the ubiquitin/proteasome pathway. NF-κB is widely
distributed in all animal cell types. Its functions are involved in cellular responses to
stress, cytokines, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens
(96). The kappa light chains of NF-κB are critical components of immunoglobulins
allows NF-κB to be crucial in the regulation of the immune responses. Generally,
inactivated NF-κB is located in the cytosol bound by the inhibitor IκBα. Once activated
by certain stimuli (e.g. leptin) (97), IκB kinase (IKK) is activated and is able to
phosphorylate the IκBα protein, leading to its ubiquitination, which results in the
separation of IκBα from NF-κB, and further degradation of IκBα by the proteosome. As a
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consequence, the activated NF-κB is translocated into the nucleus. Active NF-κB is able
to bind to the promoters of target genes, and initiate gene transcription (98). IGF-1 is able
to keep sustained activation of NF- B, but independent of IKK phosphorylation (99). In
addition, NF- B can be activated by TNF- via phosphatidylcholine-specific
phospholipase C-induced "acidic" sphingomyelin breakdown (100). TNF is also able to
activate NF-kB through MAPK and caspase pathways leading to apoptosis. Interestingly,
both TNF

and IL-1 activate NF B using MAPK signaling pathway in a synergistic

manner (101).
STAT transcription factors: Signal transducer and activator of transcription
proteins (STATs) are transcription factors, which play crucial roles in cell growth,
survival and differentiation. There are seven members in STAT family: STAT1, STAT2,
STAT3, STAT5a, STAT5b, and STAT6, which are activated by JAK. Janus kinase
phosphorylates specific tyrosine residues in the STAT protein. When the phosphorylated
dimers of STAT are activated, they are transported in the nucleus through importing a/b
and RanGDP complex. In the nucleus, STAT dimers activate transcription of target genes
by binding to their promoter regions of genes at gamma activated site (GAS) motif. The
STAT proteins are inactivated once they are de-phosphorylated by nuclear phosphatases
(102, 103). Dysregulation of the STAT pathway is involved in the formation of primary
tumours and leads to increased angiogenesis, enhanced survival of tumours and
immunosuppression (102, 103).
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Epithelial Mesenchymal Transition
Epithelial Mesenchymal Transition (EMT) is a normal developmental process
characterized by inhibition of E-cadherin expression, loss of cell adhesion and increase of
cell mobility. There are three types of EMTs (104, 105). Type 1 EMT is seen in primitive
epithelial cells transitioning to motile mesenchymal cells during gastrulation and in
primitive neuroepithelial cells which form migrating neural crest cells. Type 1 EMT is
also associated with implantation. Type 2 EMT takes place during secondary epithelial or
endothelial cells transition to resident tissue fibroblasts and is involved in wound healing,
tissue regeneration, and organ fibrosis. Thus, both Type 1 and Type 2 EMT are
associated with normal biological functions during development and wound repair,
respectively. Conversely, type 3 EMT occurs in neoplastic cells and is involved in
carcinoma cell invasion and metastasis. Carcinoma cells undergoing a type 3 EMT
invade and metastasize and thereby the primary nodules transition to metastatic tumor
cells and migrate by blood to form secondary distant nodules (106). Clarification of EMT
process at the molecular level would help to understand mechanisms of cancer
progression, detection of cancer metastases, and therapeutic intervention. There is a
variety of biomarkers to use to detect all three subtypes of EMT (Table 1.1) (105),
including cell-surface markers, cytoskeletal markers, extracellular matrix proteins,
transcription factors and micro RNAs.
Snail: The Snail family of zinc finger transcription factors, Snail1 and Snail2, are
inducers of the EMT. Snail genes are expressed in all EMT processes resulting in the
conversion of cells from epithelial to mesenchymal with migratory properties. Thus,
Snail-induced EMT is involved in formation of tissues and organs during embryonic
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development and also the invasion and metastasis of carcinoma cells during
tumorigenesis. In addition, Snail genes also act as survival factors and inducers of cell
movement independent of the induction of EMT. Snail-induced EMT is mostly due to
the repression of E-cadherin gene expression. Snail also regulates other aspects of the
EMT such as suppressing cyclin D protein , cyclin-dependent kinase 4 and the expression
of caspase, DNA fragmentation factor, Bcl-interaction death agonist, increasing MMP
expression., and increasing expression of mesenchymal cell marker such as fibronectin
and vitrionectin (105). Interestingly, pro-inflammatory cytokines and hormones released
by adipose tissue are associated with Snail stabilization. In Snail expression knockdown
inflammation-mediated breast cancer metastasis model, it shows the inhibition of
inflammatory cytokines induced EMT. Snail can be stabilized by the inflammatory
cytokine TNF through activation of the NF-kappaB pathway (107).
E-cadherin: Cadherin-1 (CDH1, E-cadherin), also known as CD324, is a tumor
suppressor gene (108). In epithelial tissues, E-cadherin is localized on the surfaces of
epithelial cells at adherent junctions and plays an important role in cell to cell adhesion
(109). Specifically, calcium-dependent interactions among E-cadherin molecules are
important to mediate and maintain the adherent junctions of epithelial cell-cell contact
(110). In cancer cells, the function of E-cadherin is associated with the dedifferentiation/
aggressiveness of tumours and the transition from transformed cells to the invasive
phenotype. In fact, E-cadherin acts as an invasion-suppressor gene. Loss of E-cadherin is
considered to be diagnostic of a poor clinical prognosis with benign lesions to invasive,
metastatic cancer. In addition, CDH1 knockout promotes cancer cell proliferation,
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invasion and metastasis, including gastric, breast, colorectal, thyroid, and ovarian cancers
(111).
ZEB1: Zinc finger E-box binding homeobox 1 (ZEB1), binds to E-box-like
elements that overlap with those bound by Snail family transcription factors. ZEB1 is
normally expressed in proliferating mesenchymal and neural progenitors. In fact, ZEB is
EMT-inducer and transcriptional repressor which promotes invasion and metastasis (112).
ZEB1 is a crucial promoter of metastasis and inhibits expression of the microRNA-200
(miR-200) family. ZEB1 links EMT-activation by suppressing stemness-inhibiting
microRNAs (miRNAs) and thereby acts as a promoter of mobile, migrating cancer stem
cells (112)(111). In cancer, overexpression of ZEB1 is associated with repression of Ecadherin. ZEB1 is expressed in most of poorly differentiated pancreatic cancers and in
invasive, undifferentiated tumor cells of pancreatic adenocarcinomas. Heterozygous
mutation of ZEB1 also leads to craniofacial abnormalities such as cleft secondary palate
and defective nasal formation. In a knockdown mouse model, decreased ZEB1 leads to
an epithelial transition without increased expression of E-cadherin and reduces not only
cancer cell invasion and metastasis, but also the number of tumor-bearing mice and the
average size of primary tumors (111).
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Table 1.1. Biomarkers for epithelial-mesenchymal transitions. Adapted from (105).
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Figure 1.1. IGF-1 and IGF-2 interact with the IGF-1 receptor (IGF-1 R), the IGF-2
receptor (IGF-2 R) and insulin receptor (insulin R). IGF1-R and insulin R are
tyrosine kinase receptors that mediate overlapping functions of the IGF ligands. The
IGF-2 R is structurally identical to the mannose 6 phosphate (M6P) receptor and
promotes degradation of the ligand. Adapted from (19).
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Figure 1.2. Free IGF-1 levels in lean and obese men and women. There is an
increased free IGF-1 level in obesity, However, less elevated free IGF-1 level in woman
compare to man. The white bars are lean, grey bars are overweight, and black bars are
obese The white bar is controls (BMI < 25), while the gray bar show moderate obesity
(25 < BMI< 30), and black bar shows severe obesity(BMI>30). Adapted from (25).
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Figure 1.3. Circulating levels of leptin (ng/ml), insulin (ng/ml), and IGF-1 (ng/ml) in
3, 6, 12, and 24 week old female B6 and LY mice. Circulating levels of leptin (ng/ml),
insulin (ng/ml), and IGF-1 (ng/ml) were measured by ELISA using blood serum collected
from 3, 6, 12, and 24 week old B6 (white bar) and LY mice (black bar). (Mack and Wood,
unpublished data)
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Figure 1.4. TNF signal transduction pathway. TNFa is responsible for the
inducible expression of genes important for diverse biological processes, including cell
growth and death, development, oncogenesis, and immune, inflammatory, and stress
responses. Adapted from (66).
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Figure 1.5. IGF-1, leptin, Il-6 and TNFa signal transduction pathways. Upon binding
to their receptors, all activate the protein kinase signaling. The phosphorylation would
cause several signal transduction cascades to be activated including (ERK1 and ERK2),
forkhead box O1 (FOXO1), glycogen synthase kinase 3 (GSK3), Janus kinase (JAK), cJun-N-terminal kinase (JNK). Adapted from (73).
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Figure 1.6. IL-6 activates the JAK/STAT pathway and the MAPK cascade. IL-6
binds to plasma membrane receptor complexes containing the common signal
transducing receptor chain gp 130 (glycoprotein 130). Signal transduction involves the
activation of JAK (Janus kinase) tyrosine kinase family members, leading to the
activation of transcription factors of the STAT (signal transducers and activators of
transcription) family. Another major signalling pathway for IL-6-type cytokines is the
MAPK (mitogen-activated protein kinase) cascade. Taken from (64).
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Figure1. 7. AP-1 functions in multistep tumorigenesis. AP-1 proteins regulate
oncogenic transformation, proliferation, apoptosis, invasive growth and angiogenesis
through modulating the expression of genes. Adapted from (86).
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CHAPTER 2
Regulation of Immediate Early and EMT Markers Genes by IGF-1 in HeLa Cells
and the Lethal Yellow Mouse Uterus
Abstract
IGF-1 can regulate differentiation, apoptosis, cell growth and survival. IGF-1
levels fluctuate during the development and progression of obesity. Furthermore, IGF-1
signaling has been implicated in abnormal cell growth associated with tumorigenesis.
Thus, these studies suggest a potential link between obesity-induced abnormalities in
IGF-1 levels and the incidence of cancer. The objective of this study was to identify IGF1 dependent changes in the expression of genes that regulate cell proliferation and
migration. In this study, HeLa cells were treated with 100ng/ml IGF-1 for 0-24 hour and
RT-QPCR was carried out using primers against immediate early (IE) genes which
regulate cell proliferation and differentiation and markers of the epithelial-mesenchymal
transition (EMT) which promote cell invasion and migration.

IGF-1 stimulated a

significant transient increase in JUN, FOS, IL-8, IL-6 and CASP10. Furthermore, SNAI1,
SNAI2 and JAG1 mRNA abundance was significantly increased by IGF-1. Interestingly,
we showed that JUN, SNAI1 and SNAI2 mRNA abundance is increased in the uterus of
our obese mouse model when circulating IGF-1 levels are increased. The signaling
pathways of AKT, ERK1/2, STAT3, and JNK likely play a role in IGF-1 dependent
regulation of IE and EMT gene expression. To assess the activity of IGF-1, cells were
treated for 0-60 minutes. Western blot analyses demonstrated the increased
phosphorylation of AKT. Furthermore, IGF-1 dependent phosphorylation of ERK1/2,
STAT3, and SPAK/JNK occurred at 15min post treatment. Thus, this study has identified
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a novel mechanism for IGF-1 dependent regulation of cell movement and survival, which
has important implications for the process of tumorigenesis.

Introduction
Obesity has been recognized as a national health threat and a major public health
challenge. Since 1980, over one billion adults considered to be overweight or obese (1)
(2). In 2007--2008, according to measured weights and heights (3), approximately 72.5
million adults in the United States were obese (CDC, unpublished data, 2010). Obese
adults are at increased risk for many diseases, such as coronary heart disease,
hypertension, stroke, type 2 diabetes, and certain types of cancer. But the mechanism by
which obesity increases the risk of cancer is unclear. In obesity, the enlarged amounts of
adipose tissue results in the distortion of the normal balance of several endogenous
hormones.
The insulin-like growth factor (IGF-1) 1 is a metabolic hormone that fluctuates
with nutrient availability. IGF-1 was once thought to be produced only by the liver and
dependent on growth hormone (GH) (4). Stimulation of the liver (and other tissues) by
GH causes the production of IGF-1. Obesity is associated with a decrease in GH. Free
fatty acids released in response to GH secretion may feedback on the hypothalamus or
pituitary as a mechanism to limit GH release (5, 6). Numerous investigators have
observed GH secretion to be diminished in obesity and reversible with weight loss (5, 6).
In vivo, protein deficiency also decreases IGF-1 levels. Likewise, nutritional repletion
causes increased IGF-1 production. It is reported that IGF-1 resistance becomes evident
in obese individuals similar to insulin and leptin resistance. Furthermore, in obesity free
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IGF-1 levels are actually increased in obese men and to a lesser extent in woman,
suggesting GH-independed changes in IGF-1 synthesis (7). IGF-1 is now known to be
produced in a wide variety of organs and tissues, especially produced by adipose tissue
(4). The increased amounts of IGF-I could be secreted from the excessively enlarged
amounts of adipose tissue (8). In addition, free fatty acids may increased sensitivity to
feedback effects of IGF-1 or increased free IGF-1 concentrations in obesity (7, 9). The
increased free IGF-1 may affect cell growth and development which is related to
tumorigenesis. The current study suggests a relationship between increased IGF-1 and
cancer tumorigenesis.
In the current study, the objective is to identify IGF-1 dependent changes in the
expression of genes associated with cell transformation and/or migration. To address this
objective, two models were used, an immortalized cell line and a mouse model of
obesity. HeLa cells are an immortal cell line used in scientific research, including cancer
research, AIDS, the effects of radiation and toxic substances (10). The HeLa cell which
was derived from cervical carcinoma, is a good in vitro model for immortal, grows
indefinitely. The LY (LY, Ay/a) mouse has a gene deletion between the promoter and
first exon region of the agouti gene, which results in ectopic over expression of the agouti
protein (11, 12). The over expressed agouti binds to melanocortin-4 receptors (MCR4) as
an antagonist of -MSH in hypothalamus and in the skin. In hypothalamus, the over
expressed agouti interferes with normal satiety control and causes over-eating (figure
2.6.). In the skin, it results in a yellow coat color. Thus, the LY (LY, Ay/a) mouse is
model can be used to mimic the mechanism of obesity development in humans.
Furthermore, previous data from our lab shows the increased IGF-1 levels in the 6 week
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old LY mouse compared to the wild-type C57BL/6 control mouse (Mack and Wood,
unpublished data). With the increased IGF-1 level and overweight, the LY is good vivo
model which can be used to determine the relationship between obesity dependent
increasing IGF-1 and the expression of genes associated with cancer tumorigenesis.

MATERIALS AND METHODS

HeLa cell culture and whole cell protein extracts: 500,000 HeLa cells (American
Type Culture Collection, Manassas, VA) were cultured in 10 cm dish with Eagle’s
Minimum Essential Medium pH 7.4 (Sigma, St. Louis, MO), containing 1.5 g/L
NaHCO3, 0.11 g/L Sodium pyruvate, 0.292 g/L L-glutamine, 10 ml/L Penn-strep, 1 ml/L
phenol red and 100 ml/L of heat inactivated FBS (Hyclone, Logan, UT, USA). After 24h,
the cells were changed to the same medium except there was no FBS included for serum
starvation. After 24h serum starvation, cells were treated with 100ng/ml IGF-1 (Cell
Signaling Technology, Danvers, MA) for 0, 15, 30 or 60 minutes. The cells were washed
with 1X HBSS (Invitrogen, Carlsbad, CA, USA) and cells collected in RIPA buffer (150
mM NaCl, 1 mM EDTA, 50mM Tris-HCl pH7.4, 1% NP-40, 0.25% Na-deoxycholate)
containing phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4) and Complete Mini
Protease Inhibitor Cocktail (Roche Diagnostics). Cells in the RIPA buffer were sonicated
15 seconds and then centrifuged at 10,000 x g for 5 minute to separate cell debris and the
supernatant which contain soluble protein. The protein concentration of each
experimental replicate was determined with the Pierce BCA Protein Assay (Rockford, IL,
USA).
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HeLa cell culture and RNA extraction: 200,000 HeLa cells (American Type
Culture Collection, Manassas, VA) were cultured in 3.5 cm dish and serum starved for 24
h as described above. After serum starvation, cells were treated with 100ng/ml IGF-1
(Sigma, St. Louis, MO) for 0, 0.25, 0.5, 1, 2, 4, 8, 16 or 24 h. The cells were washed with
1X HBSS (Invitrogen, Carlsbad, CA, USA) and then collected in TRI reagent (Ambion
Inc., Austin, TX, USA). Total RNA was extracted according to the manufacturer’s
protocol (Sigma, St. Louis, MO). After isolation, the total RNA was dissolved in 20 μl
diethyl pyrocarbonate (DEPC) water. The RNA concentration was determined using
Beckman Coulter DU 730 Life Science UV/Vis Spectrophotometer.
Reverse Transcription: Total HeLa cell RNA (5 g) was mixed with 5 units of
RQ1 RNase free DNase (Promega, Madison, WI), M-MLV RT buffer and DEPC water
and incubated at 37°C for 30 minutes to remove genomic DNA contaminants. Before
RT-PCR, 1.1 μl of RNA and RQ1 mix was removed from each sample to a new tube with
15 μl DEPC water, which should be used as No RT to detect the residual genomic DNA.
The mixed RNA samples was subsequently combined with 2 μl Random

primers

(Promega), 2 μl dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 2.4 μl
DEPC water, and then were incubated in 65°C for 5 min. After that, the mixed samples
were chilled on the ice quickly. 400 units of Moloney Murine Leukemia Virus reverse
transcriptase (Promega), 3.2 μl of RT buffer (Invitrogen, Carlsbad, CA), and 2 μl 0.1 M
DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA) were added into each sample. The
mixed samples were incubated at 37°C for 2 hour and followed by 15 min at 72°C to stop
the reverse transcriptase. The cDNA was stored at -20°C for subsequent real time-PCR.
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Quantitative, Real-Time PCR (qPCR) Analysis:

Gene-specific forward and

reverse primers were designed (Primer Express, Applied Biosystems, Foster City, CA)
and synthesized (Integrated DNA Technologies, Coralville, IA) and store at -20°C. The
information of the primers and probes are shown in table 2.1 and table 2.2. Each set of
gene-specific primers was tested to determine the maximal concentration of primers that
could be used to produce specific amplification of the target sequence without primer
dimer amplification. Before use, each cDNA sample was diluted 1:10. Glyceradehyde-3phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and used as a control for
reverse transcription efficiency and well-to-well variation in template. PCR was
performed with 10 μl Taqman Universal Master Mix (Applied Biosystem, Foster City,
CA), 1 μl cDNA, 1 μl probe with primers, and 8 μl DEPC to make up the reaction
volume to 20 μl. QRT-PCR was performed in 364 well plates (Axygen Scientific, Union
City, CA) with an adhesive cover film (VWR, Scientific Products, North Kansas City,
MO) in 7900HT Fast Real-Time PCR system (Applied Biosystems). Quantitative PCR
(qPCR) reactions of the other target genes were carried out using 1:10 dilutions of each
cDNA sample and standard samples with Power SYBR Green PCR Master Mix (Applied
Biosystem, Foster City, CA). All experimental and Gapdh PCRs were carried out in
separate wells in triplicate. These relative values are plotted against the threshold value
for each dilution to generate a standard curve. An arbitrary value of template was
assigned to the highest standard and corresponding values were assigned to the
subsequent dilutions. According to the slope and y-intercept of the standard curve,
7900HT Fast Real-Time PCR system assigned a value of the relative amount for each
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experimental and Gapdh triplicate. The value of the average of the experimental triplicate
divided by the average of the Gapdh triplicate was used for statistical analysis.
Western Blot Analyses: The protein samples were resolved by SDSpolyacrylamide 10% gel electrophoresis which contains 4% stacking gel and 10%
separating gel. Protein samples were loaded together with loading buffer and the
separated protein was transferred to Immobilon PVDF (Millipore, Billerica, MA).
Following transfer, the membranes were blocked with 5% nonfat dry milk in 1X TBST
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% (v/v) Tween 20) for 1 hour with gentle
shaking in order to block the nonspecific proteins. After that, the blots were probed with
the primary antibodies which are diluted in 5% w/v BSA, 1XTBS, 0.1% Tween 20. The
membrane was then incubated with primary antibody against phospho-AKT (Cell
Signaling Technology), phospho-ERK1/2 (Cell Signaling Technology), phospho-JNK, or
phospho-STAT3 overnight at 4°C with gentle shaking. Blots were washed with 1X TBST
and incubated for 1 hour with HRP-conjugated secondary antibody which was diluted
with 5% nonfat dry milk in 1X TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01%
(v/v) Tween 20). Proteins were incubated with West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL) for 5 min and exposed to autoradiograph film (Fisher Scientific,
Fairlawn, IL) in dark room. After the visualization of phosphorylated protein, the blots
were stripped with Restore plus Western Blot Stripping Buffer (Pierce) in room
temperature for 20 min and 37°C 10 min. Wash the blots with 1X TBST and blocked
with 5% milk in 1XTBST. Next, incubated with primary antibody against total AKT,
total ERK1/2, total JNK, or total STAT3 (Cell Signaling Technology) overnight at 4°C
with gentle shaking. Total protein was exposed and visualized as described above. The
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visualized total protein served as a loading control for each sample. The autoradiograph
images films were scanned and the density of the protein band was determined in
Photoshop. Semi-quantitative analysis of band density of the phosphorylated and total
protein

was

calculated

in

each

film

as

described

by

Miller

(http://lukemiller.org/journal/2007/08/quantifying-western-blots-without.html).

The

amount of phosphorylated protein was normalized by total protein expressed in each
sample. The normalized abundance of phosphorylated protein of each sample was
subsequently compared to the untreated control sample. The data was showed as a foldchange.
Animals: C57BL/6 (B6; C57BL/6 a/a) and Lethal Yellow (LY; C57BL/6 Ay/a)
female mice were used in the experiment, which the Founder mice were bought from
Jackson Laboratory (Bar Harbor, ME, USA). All animal protocols were approved by the
University of Nebraska Institute of Animal Care and Use Committee (IACUC) according
to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
According the animal protocols, all the Mice were fed with standard rodent chow and
fresh water. The mice were housed in cages at virus-free room in a 12/12 hour light/dark
cycle. Each cage owns no more than 5 mice.
Statistical Analyses: All statistical analyses were carried out by GraphPad Prism
4.0 (Graphpad Software, La Jolla, CA). QPCR data and Western blot data were analyzed
using one-way ANOVA. Differences in data were considered statistically significant at P
< 0.05. Different letters indicate significant differences in fold change in mRNA
abundance compared to control for all qPCR data and phospho-protein/total protein ratio
in time course. The Error bars represent mean

SE.
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Results
Significant gene expression differences In HeLa cells
To clarify the roles of IGF-1 in the regulation of immediate early genes, HeLa
cells were treated with 100ng/ml IGF-1 in a time course after 24h serum starvation. JUN
mRNA expression was elevated at 2 h compared to untreated control. The mRNA
expression decreased gradually over time reaching control levels by 24 h. IGF-1
dependent increase in FOS was maxed at 0.25 hour and began to decrease quickly at 0.5
hour. For inflammatory response cytokines, IGF1 induced 5-fold increase of IL-8 mRNA
at 4 h, but the decreased to control level at 16 h. IGF-1 caused fluctuations in MCP-1 and
IL-6 over the time course evaluate but these changes were not significant.

As an

important pro-apoptotic factor, caspase 10 mRNA abundance was increased at 4 h to 1.5
times than control (Fig 2.2).
IGF-1 also regulates the mRNA abundance of markers of the epithelialmesenchymal transition in HeLa cells (Fig. 2.3). IGF-1 induced mRNA expression level
of SNAI1 2.5-fold at 2 h, compared to untreated control (Fig 2.3). SNAI2 mRNA was
also increased by 3-fold but at an earlier time point (at 0.25 hour) and decreased back to
control level by 1.5 h. IGF-1 did not change mRNA expression of ZEB2 and TWIST1.
Furthermore, IGF-1 only had a modest effect on JAG1 mRNA abundance at 2-4 h posttreatment.
Significant gene expression differences between LY and age matched B6 controls.
To determine the potential role of altered IGF-1 levels in an obese mouse model
on immediate early and epithelial-mesenchymal transition marker gene expression, RNA
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was collected from uterus tissues of lethal yellow (LY) and C57BL/6 (B6) wild-type
control mice. Fig 2.1 indicated that Snai1, Snai2 and Fos have 1.5-fold increase in
mRNA abundance in uterus tissues of LY compared to age-matched B6 mice. For Jun,
mRNA abundance in LY uterus is 2 times higher compared to age-matched B6.
Signaling Pathways regulated by IGF-1 in HeLa cells
To further clarify the pathways that potentially mediate IGF-1 effects on the
immediate early gene expression and epithelial-mesenchymal transition marker gene
expression, we examined the phosphorylation of AKT and ERK1/2 in untreated and IGF1 treated cells. In Fig 2.4., the level of AKT phosphorylation increased dramatically (5fold) compared to the untreated control 15 min after the treatment of 100 ng/ml of IGF-1,
and maintained this fold increase through the 1 hour time point. For ERK1/2, 100 ng/ml
of IGF-1 induced phosphorylation by 3-fold by15 min, and interestingly, after that, the
phosphorylation level of ERK dropped back to initial level by 30 minutes post-treatment.
Fig 2.5 showed that 100 ng/ml of IGF-1 induced phosphorylation of pSAPK/JNK by 3fold increase in 15 min, whereas after that, the phosphorylation level dropped back to
initial level in another 15 minutes, while pSTAT3,its level increased by 2 fold in 15
minutes and kept dropping down in another 30 minutes.

Discussion
FOS and JUN belong to the AP-1 transcription factor family, which is involved in
a large variety of biological processes such as cell differentiation, proliferation, apoptosis
and oncogenic transformation. According to Liu's report, AP-1 activities were increased
in the peritumoral tissue. AP-1 converts extracellular signals into cell and make changes

46
of expression of specific target genes which harbour AP-1 binding site(s) in their
promoter or enhancer regions (13-15).
AP-1 proteins participate in tumorigenesis by regulating oncogenic
transformation, proliferation, apoptosis, invasive growth and angiogenesis. Fos and FosB
are dispensable for cell cycle progression, for example, fibroblasts and embryonic stem
cells have no proliferation defect if lacking these components (16-18). In addition,
Preston reported the overexpression of c-Fos induces cell death and resistant to apoptosis
in an embryonic Syrian hamster cell line (19). However, c-Jun would act as both a
positive and a negative modulator of apoptosis. In fact, dependent on its ability to
heterodimerize with Jun proteins and to bind to DNA, c-Fos acts as oncogenic. Overexpressed c-Fos transforms chondroblasts and osteoblasts, and can therefore induce
tumorigenesis (20, 21). Here, we demonstrated that IGF-1 is able to regulate the
expression of FOS and JUN in HeLa cells. That the dramatic induction of JUN and FOS
mRNA level caused by IGF-1, might open a new way to disclose the mechanism that
IGF-1 uses activator protein 1 (AP-1) to turn on plenty of downstream target genes
related to the initiation of tumorigenesis.
In mouse development and tumorigenesis model by Jochum’s, C-Jun binds to the
promoter of the P53 and Cyclin D1, and then inhibit the p53 gene expression and
stimulate the cycline D1 gene expression. C-Fos and FosB also binds to the promoter of
the CyclinD1 and stimulates the gene expression of CyclinD1 (15). Furthermore, in our
mouse model, there is increased blood level of IGF-1 in the LY mouse compared to B6
mouse (Fig. 1.3). Circulating free IGF-1 levels are actually increased in obese men and to
a lesser extent in woman (7). With the increased IGF-1 level and obesity, the LY (LY,
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Ay/a) mouse is excellent vivo model for obesity. The increased IGF-1 could cause the
unbalanced IGF-1 environment in the LY uterus. Moreover, the qPCR shows the
increased mRNA expression of Fos in uterus in LY mouse at 6 weeks, which is the onset
of obesity. This change is similar as IGF-1 treated in vitro model of HeLa cells.
Therefore, our data suggest IGF-1’s roles on cell growth, death, and tumorigenesis is
possibly mediated by AP-1 pathway in obesity, which may suggest a new key to
understand the relationship between obesity and reproductive tract cancer.
In our HeLa cells model, IGF-1 is able to induce an important inflammation factor
IL-8 mRNA level with an increase of 4.5 fold in 4 h. Few data showed this fact.
Therefore, this is a novel finding. IL-8 is a chemokine, secreted by macrophages,
epithelial cells, endothelial cells, also by adipose cells. Increased expression of IL-8
and/or its receptors has been characterized in cancer cells by its contribution to cancer
progression and metastasis (22, 23). IL-8 signaling promotes angiogenic responses in
endothelial cells by increasing proliferation and survival of endothelial and cancer cells,
and infiltrating neutrophils (22). The IGF-1 related increase of IL-8 increase the risk of
cancer. Our data indicated that AP-1 subunits mRNA level could be increased by IGF-1
earlier than did IL-8. Consequently, AP-1 might possibly link a bridge between IGF-1
and IL-8.
The epithelial-mesenchymal transition (EMT) occurs not only during normal
development but also in neoplastic cells which to promote invasion and metastasis (24).
The snail family, SNAI1 and SNAI2, is important EMT makers. The zinc-finger
transcription factor snail induced EMT involved in the invasion and metastasis of
carcinoma cells during tumorigenesis. Perez-Mancera reported that Snail expression is
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frequently upregulated in individuals with cancer (25). Our data demonstrated IGF-1
dependent increase in SNAI1 and SNAI2 mRNA in HeLa cells. Interestingly, there is
also a significant increase of mRNA expression of SNAI1 and SNAI2 in LY mouse
uterus in 6 weeks when compare to the B6 control mouse. Together with the increased
IGF-1 level in the 6 week LY mouse, the increased SNAIL family in our vivo and in vitro
model may show us another key to understand the obesity dependent unbalance IGF-1
level function in reproductive tract cancer.
Pro-inflammatory cytokines and hormones released by adipose tissue can
generate a chronic inflammatory profile which may be associated with Snail protein
stabilization. In Snail expression knockdown inflammation-mediated breast cancer
metastasis model, it shows the inhibition of inflammatory cytokines reduced cell
migration (26, 27). The increased IL-8 related to IGF-1 in HeLa cell may be associated to
Snail family stabilization. Furthermore, there is a link between Snail expression and AP1. In human skin keratinocytes, AP-1 is able to induce SNAIL expression in the exposure
of Ultraviolet (UV) irradiation (28). Inhibition of AP-1 activity by over-expression of
dominant-negative c-Jun extremely decreased Snail induction. Analyses of the Snail
promoter revealed the presence of an AP-1 binding site. EMSA assay demonstrated that
UV irradiation specifically induced c-Jun binding to this AP-1 site. Mutation of the AP-1binding site completely blocked protein binding and inhibited UV irradiation-induced
Snail promoter activity (27, 28). Thus, the increased AP-1 expression in obesity may
cause not only increased tumorigenesis but also increased metastasis due to the AP-1
induced increase of Snail family protein. Together, these data suggest IGF-1, SNAI1/2
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and FOS/JUN are important player in obesity and obesity related cancers. Clarification of
their mechanism provides a promising way for the clinical therapy.
It is critical to figure out the mediating pathways which transfer IGF-1's signal.
IGF-I stimulates phosphorylation of the IRS-1 complex , and then cause several signal
transduction cascades to be activated including the PI3K pathway, which in turn activates
the AKT pathway (29). Furthermore, low IGF-I decreases cancer due to attenuation of
AKT and mTOR signaling pathways. Consequently, epidermal response to tumor
promotion is diminished (29, 30). IGF-1 can stimulate AP-1 and c-jun N-terminal kinase
(JNK) activation in retina according to Poulaki report (31). Using systemic inhibition of
IGF-I signaling with a receptor-neutralizing antibody, or with inhibitors of PI-3 kinase
(PI-3K), c-Jun kinase (JNK), or AKT, it shows a suppressed retinal AKT, JNK and AP-1
activity. In addition, intravitreous administration of IGF-I increased retinal AKT, JNK
and AP-1 activity (31). Our western-blot data demonstrated that IGF-1 is sufficient to
activate AKT, ERK, JNK, and STAT immediately at 15 minutes which is same as the
report by Taniguchi. This provides a clue that AKT, ERK, JNK, and STAT are mediator
to deliver IGF-1 signal to increase some downstream target gene expression, including
regulation of IE and EMT gene expression. In the screening through chemical
inhibitors, Snail induction is reduced by inhibitors of ERK and JNK.
IGF-1 is one of the important unbalanced hormones in obesity. While there are
reports about decreased circulating IGF-1 levels or no difference in IGF-1 levels between
obese and normal-weight individuals, our lab’s in vivo study show circulating levels of
IGF-1 were significantly increased in the LY compared to B6 controls at 6 weeks.
Together with the vitro data with IGF-1 treatment in HeLa cells, this study has identified
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a novel mechanism for important relationship between obesity dependent IGF-1 and
reproductive tract cancer. It is may be another key to understand a plausible mechanism
for obesity-dependent increases in cancers of the female reproductive tract.
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Table 2.1. Human Primer sequences used for QPCR analysis
Gene

CASP10
FOS
JUN
MCP-1
IL-6
IL-8
SNAI1
SNAI2
TWIST1
ZEB2
JAG1
GAPDH

Probe
Dye

Primer

Sequence (5' to 3')

SYBR Green

Forward GGAGCTGTCTACTCTTCGGATGA
Reverse AGGGCTGTGAAGTGAGACATGAT
SYBR Green
Forward CCTCGCCCGGCTTTG
Reverse GCCTCGTAGTCTGCGTTGAAG
SYBR Green
Forward CTGGGAGGACCGGAGACA
Reverse GAGAAGCCTAAGACGCAGGAAA
SYBR Green
Forward CAAGCAGAAGTGGGTTCAGGAT
Reverse TCTTCGGAGTTTGGGTTTGC
Forward AGGGCTCTTCGGCAAATGTA
SYBR Green
Reverse GAAGGAATGCCCATTAACAACAA
Forward CTGGCCGTGGCTCTCTTG
SYBR Green
Reverse CCTTGGCAAAACTGCACCTT
Forward CCCCAATCGGAAGCCTAACT
SYBR Green
Reverse GCTGGAAGGTAAACTCTGGATTAGA
Forward CCTGGGCGCCCTGAA
SYBR Green
Reverse TTCTCCCCCGTGTGAGTTCT
Forward TCCGCGTCCCACTAGCA
SYBR Green
Reverse AGTTATCCAGCTCCAGAGTCTCTAGAC
Forward CCAGCTCGAGCGGCATA
SYBR Green
Reverse GCCACACTCTGTGCATTTGAA
Forward CAGCTCTGTGACAAAGATCTCAATTAC
SYBR Green
Reverse AGGGCCTGTGTTGCTACAAGTT
Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems
(VIC Probe)

Table 2.2. Mouse Primer sequences used for QPCR analysis
Gene

Fos
Jun
Snai1
Snai2
Gapdh

Probe
Dye
SYBR Green

Primer

Sequence (5' to 3')

Forward CCCCAAACTTCGACCATGAT
Reverse GGAGGATGACGCCTCGTAGTC
SYBR Green
Forward CCGCCCCTGTCCCCTAT
Reverse TCCTCATGCGCTTCCTCTCT
Forward GCCTGTGCCCGAACCTT
SYBR Green
Reverse GCCAGACTCTTGGTGCTTGTG
Forward GCCTGGGTGCCCTGAAG
SYBR Green
Reverse TTGCAGACACAAGGCAATGTG
Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems
(VIC Probe)
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Figure 2.6. Lethal yellow mouse model. The LY mouse own a gene deletion in the
promoter and first exon region of the agouti gene which locus on the C57BL/6
background. The deletion causes the ubiquitous expression of the agouti gene. Overexpressed agouti acts as an antagonist of a-MSH by binding to melanocortin-4 receptors
(MCR4) in the hypothalamus. Therefore, over-expressed agouti protein interfers with
normal satiety control. As a consequence, the LY mice overeat resulting in the
development of obesity.
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CHAPTER 3
Regulation of Immediate Early and EMT Markers by leptin in HeLa Cells

Abstract
Obesity increases the risk factor in various cancers including breast, endometrial,
ovarian, prostate cancer esophagus, gastric, colon cancer, leukemias. Leptin acts as
significant role in the pathophysiology of obesity. Given that, the increased leptin level in
obese individuals, the study suggests the relationship of leptin’s link to cancer risk is of
such considerable importance. In the current study, after 24h serum starvation, HeLa cells
were treated with 100ng/ml leptin for 0, 0.5,1,2,4 or 8 hours. After treatment, RNA was
collected and quantitative PCR (QPCR) was carried out using primers against immediate
early (IE) genes JUN, FOS, IL-8, IL-6, MCP-1 and CASP10 and epithelial-mesenchymal
transition (EMT) marker genes SNAI1, SNAI2, Twist, CDH1, ZEB2. Leptin stimulated a
significant transient increase in JUN, IL-6 and MCP-1 with the peak showing at 8 hour.
The signaling pathways including ERK1/2, STAT3, and SAPK/JNK is important for the
regulation of the IE and EMT. Western blot analyses demonstrated increased
phosphorylation of STAT3, and SAPK/JNK by leptin in HeLa cells. In all, this study has
identified a novel mechanism for important relationship between leptin and cancer in
obesity. It may be another key to understand cancer and provide new methods to care
cancer.
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Introduction
Obesity is a prevalent condition which is often stigmatized. Nearly two-thirds of
the United States population is overweight. Since 1980, more than one-third of the
population are at least 20% above their normal weight in the USA, and this proportion is
increasing (3, 4). Increasingly, obesity has become a serious medical problem in
developing nations with urbanization and a more plentiful food supply. However, obesity
is not just meaning too much fat, in fact, it reduce life expectancy is reduced when bodymass index (BMI, body mass index) is 20% or more above normal (1). Furthermore,
obesity is followed with the increased likelihood of various diseases, including heart
disease, type 2 diabetes, high blood pressure, weight-bearing arthritis , asthma and
certain types of cancers (2).
In individuals, energy balance is normally controlled by a feedback loop which
interacts with the satiety center in the brain, which maintains constancy of total body
energy stores. In the obese phenotype, there is an increase in plasma leptin suggesting
that obesity results in resistance to leptin and disruption of satiety control which further
exacerbates the obesity. In recent years, leptin has become a focus for obesity-dependent
diseases because the key role to balance energy intake.
Leptin is from the Greek word "leptos," meaning thin. It is a peptide hormone of
16kDa and 167 amino acids; one of the important adipose derived hormones which
regulates energy intake and expenditure. Leptin is the product of the "obesity" (ob) gene
which is discovered in 1994 by Zhang (5). In an individual, leptin is expressed primarily
by the adipocytes of white adipose tissue and, at lower levels, in gastric epithelium and
placenta (6, 7). In the central nervous system, leptin interacts with the complex pathways
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and also through direct peripheral mechanisms. Leptin acts as a mediator of energy
expenditure (8); as a permissive factor to mediate puberty (9); as a signal of metabolic
status during pregnancy to modulate the fetus and the maternal metabolism (10); and as a
mediator to interact with other hormones to regulate the energy status and metabolism
including insulin, the insulin-like growth factors, growth hormone and glucocorticoids
(11-13). Leptin was considered as a great hope to be the successful treatment of obesity
for scientific and clinical communities. But it is just a dream to use leptin to treat obesity.
The complex leptin axis and the existence of leptin resistance in most obesity make the
dream gone with wind. However the role of the leptin axis is now being shown to have
more functions than it was first discovered. Complex interactions between hormone axes
in the periphery are integral in maintaining homeostasis of a diverse range of functions.
Though obesity is recognized as an established risk factor in various cancers; it is
only recently that studies have established a link between leptin and cancer. For example,
leptin was reported to play an important role in serious human reproduction cancers such
as breast, endometrial, ovarian and prostate cancer (14-17). Leptin promotes the growth
of malignant cells by activating signal transducer and activator of transcription 3
(STAT3) and kinase (ERK) 1/2 pathways in breast cancer (18). Leptin might be a
potential regulator for ovarian cancer, as leptin receptors were identified in ovarian
surface epithelium and ovarian cancer cell lines (16). Obesity, a situation characterized
by high levels leptin, has also been examined as a potential increased risk factor for
prostate cancer but there is no clear evidence to support a strong pathogenic link between
obesity and prostate cancer (17, 19). However, leptin may cause the alterations of the
balance of sexual hormones, which result in increased risk of prostate cancer (17, 19). In
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all, leptin could be one of the important key to determine the reason of the increased risk
of cancer in obesity.

MATERIALS AND METHODS

HeLa cell culture and whole cell protein extracts: 500,000 HeLa cells (American
Type Culture Collection, Manassas, VA) were cultured in 10 cm dish with Eagle’s
Minimum Essential Medium pH 7.4 (Sigma, St. Louis, MO), containing 1.5 g/L
NaHCO3, 0.11 g/L Sodium pyruvate, 0.292 g/L L-glutamine, 10 ml/L Penn-strep, 1 ml/L
phenol red and 100 ml/L of heat inactivated FBS (Hyclone, Logan, UT, USA). After 24h,
the cells were changed to the same medium except there was no FBS included for serum
starvation. After 24h serum starvation, cells were treated with 100ng/ml leptin (Sigma,
St. Louis, MO) for 0, 15, 30 or 60 minutes. The cells were washed with 1X HBSS
(Invitrogen, Carlsbad, CA, USA) and cells collected in RIPA buffer (150 mM NaCl, 1
mM EDTA, 50mM Tris-HCl pH7.4, 1% NP-40, 0.25% Na-deoxycholate) containing
phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4) and Complete Mini Protease
Inhibitor Cocktail (Roche Diagnostics). Cells in the RIPA buffer were sonicated 15
seconds and then centrifuged at 10,000 x g for 5 minute to separate cell debris and the
supernatant which contain soluble protein. The protein concentration of each
experimental replicate was determined with the Pierce BCA Protein Assay (Rockford, IL,
USA).
HeLa cell culture and RNA extraction: 200,000 HeLa cells (American Type
Culture Collection, Manassas, VA) were cultured in 3.5 cm dish and serum starved for 24
hours as described above. After serum starvation, cells were treated with 100ng/ml leptin
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(Sigma, St. Louis, MO) for 0, 0.25, 0.5, 1, 2, 4, or 8 hours. The cells were washed with
1X HBSS (Invitrogen, Carlsbad, CA, USA) and then collected in TRI reagent (Ambion
Inc., Austin, TX, USA). Total RNA was extracted according to the manufacturer’s
protocol (Sigma, St. Louis, MO). After isolation, the total RNA was dissolved in 20 μl
diethyl pyrocarbonate (DEPC) water. The RNA concentration was determined using
Beckman Coulter DU 730 Life Science UV/Vis Spectrophotometer.
Reverse Transcription: Total HeLa cell RNA (5 g) was mixed with 5 units of
RQ1 RNase free DNase (Promega, Madison, WI), M-MLV RT buffer and DEPC water
and incubated at 37°C for 30 minutes to remove genomic DNA contaminants. Before
RT-PCR, 1.1 μl of RNA and RQ1 mix was removed from each sample to a new tube with
15 μl DEPC water, which should be used as No RT to detect the residual genomic DNA.
The mixed RNA samples was subsequently combined with 2 μl Random

primers

(Promega), 2 μl dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 2.4 μl
DEPC water, and then were incubated in 65°C for 5 min. After that, the mixed samples
were chilled on the ice quickly. 400 units of Moloney Murine Leukemia Virus reverse
transcriptase (Promega), 3.2 μl of RT buffer (Invitrogen, Carlsbad, CA), and 2 μl 0.1 M
DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA) were added into each sample. The
mixed samples were incubated at 37°C for 2 hour and followed by 15 min at 72°C to stop
the reverse transcriptase. The cDNA was stored at -20°C for subsequent real time-PCR.
Quantitative, Real-Time PCR (qPCR) Analysis:

Gene-specific forward and

reverse primers were designed (Primer Express, Applied Biosystems, Foster City, CA)
and synthesized (Integrated DNA Technologies, Coralville, IA) and store at -20°C. The
information of the primers and probes are shown in table 3.1. Each set of gene-specific
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primers was tested to determine the maximal concentration of primers that could be used
to produce specific amplification of the target sequence without primer dimer
amplification. Before use, each cDNA sample was diluted 1:10. Glyceradehyde-3phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and used as a control for
reverse transcription efficiency and well-to-well variation in template. PCR was
performed with 10 μl Taqman Universal Master Mix (Applied Biosystem, Foster City,
CA), 1 μl cDNA, 1 μl probe with primers, and 8 μl DEPC to make up the reaction
volume to 20 μl. QRT-PCR was performed in 364 well plates (Axygen Scientific, Union
City, CA) with an adhesive cover film (VWR, Scientific Products, North Kansas City,
MO) in 7900HT Fast Real-Time PCR system (Applied Biosystems). Quantitative PCR
(qPCR) reactions of the other target genes were carried out using 1:10 dilutions of each
cDNA sample and standard samples with Power SYBR Green PCR Master Mix (Applied
Biosystem, Foster City, CA). All experimental and Gapdh PCRs were carried out in
separate wells in triplicate. These relative values are plotted against the threshold value
for each dilution to generate a standard curve. An arbitrary value of template was
assigned to the highest standard and corresponding values were assigned to the
subsequent dilutions. According to the slope and y-intercept of the standard curve,
7900HT Fast Real-Time PCR system assigned a value of the relative amount for each
experimental and Gapdh triplicate. The value of the average of the experimental triplicate
divided by the average of the Gapdh triplicate was used for statistical analysis.
Western Blot Analyses: The protein samples were resolved by SDSpolyacrylamide 10% gel electrophoresis which contains 4% stacking gel and 10%
separating gel. Protein samples were loaded together with loading buffer and the
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separated protein was transferred to Immobilon PVDF (Millipore, Billerica, MA).
Following transfer, the membranes were blocked with 5% nonfat dry milk in 1X TBST
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% (v/v) Tween 20) for 1 hour with gentle
shaking in order to block the nonspecific proteins. After that, the blots were probed with
the primary antibodies which are diluted in 5% w/v BSA, 1XTBS, 0.1% Tween 20. The
membrane was then incubated with primary antibody against phospho-AKT (Cell
Signaling Technology, Danvers, MA), phospho-ERK1/2 (Cell Signaling Technology),
phospho-SAPK/JNK (Cell Signaling Technology), or phospho-STAT3 (Cell Signaling
Technology) overnight at 4°C with gentle shaking. Blots were washed with 1X TBST
and incubated for 1 hour with HRP-conjugated secondary antibody which was diluted
with 5% nonfat dry milk in 1X TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01%
(v/v) Tween 20). Proteins were incubated with West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL) for 5 min and exposed to autoradiograph film (Fisher Scientific,
Fairlawn, IL) in dark room. After the visualization of phosphorylated protein, the blots
were stripped with Restore plus Western Blot Stripping Buffer (Pierce) in room
temperature for 20 min and 37°C 10 min. Wash the blots with 1X TBST and blocked
with 5% milk in 1XTBST. Next, incubated with primary antibody against total AKT,
total ERK1/2, total SAPK/JNK, or total STAT3 (Cell Signaling Technology) overnight at
4°C with gentle shaking. Total protein was exposed and visualized as described above.
The visualized total protein served as a loading control for each sample. The
autoradiograph images films were scanned and the density of the protein band was
determined in Photoshop. Semi-quantitative analysis of band density of the
phosphorylated and total protein was calculated in each film as described by Miller
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(http://lukemiller.org/journal/2007/08/quantifying-western-blots-without.html).

The

amount of phosphorylated protein was normalized by total protein expressed in each
sample. The normalized abundance of phosphorylated protein of each sample was
subsequently compared to the untreated control sample. The data was showed as a foldchange.
Statistical Analyses: All statistical analyses were carried out by GraphPad Prism
4.0 (Graphpad Software, La Jolla, CA). QPCR data and western-blot data were analyzed
using one-way ANOVA. Differences in data were considered statistically significant at P
< 0.05. Different letters indicate significant differences in fold change in mRNA
abundance compared to control for all qPCR data and phospho-protein/total protein ratio
in time course. The Error bars represent mean

SE.

Results
Significant gene expression differences In HeLa cells by Leptin
To evaluate effects of leptin on the immediate early gene expression, HeLa cells
were treated with 100 ng/ml leptin after 24-hour serum starvation. The abundance of
each mRNA transcript was analyzed by quantitative real-time PCR (qPCR). These
analyses indicated that JUN ,FOS , IL-8 and CASP10 are modestly increased 0.5 hours
after leptin treatment, although statistically insignificant, as compared to control. MCP-1
and IL-6 began to show a trend of increased mRNA at 0.5 hour. At 8 hours, their mRNA
increased significantly by 1.5- and 2-fold, respectively compared to untreated control
cells (Fig 3.1). Conversely, 100 ng/ml of leptin had no effect on mRNA level of
epithelial-mesenchymal transition marker gene expression, including SNAI1, SNAI2,
Twist, ZEB2, and JAG1. There is no significant difference in mRNA abundance
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compared to untreated control cells at any time point (Fig. 3.2).

Signaling Pathways regulated by leptin in HeLa cells
ERK1/2 and JNK-STAT pathways are important mediators of leptin effects on
cell function. In Fig 3.3, 100 ng/ml of leptin only had a modest effect on the
phosphorylation of ERK1/2 over the time course. Specifically, phosphorylated ERK1/2
was increased by 1.5 fold in 15 minutes. In Fig 3.4, leptin increased SAPK/JNK and
STAT3 phosphorylation by 1.5- or 2- fold, respectively as early as 15 minutes after
treatment. After that, SAPK/JNK phosphorylation began to decrease toward untreated
control levels, but increased STAT3 phosphorylation level was maintained over the entire
time course.

Discussion
Obesity, characterized by high levels of leptin, has also been examined as a potential
increased risk factor for cancer but there is no clear evidence to support a strong pathogenic link
between leptin and cancer. However, leptin cause the alterations of the balance of sexual
hormones, which result in increased risk of prostate cancer (17, 19). Leptin was reported to

play an important role in a serious human reproduction cancer such as breast,
endometrial, ovarian and prostate cancer (14-17). Recently, more and more attentions
were focused on unbalance hormone level in obesity, such as leptin. The leptin levels,
which play an important role in obesity , were compared between LY and B6 males and
females (20, 21). According to the previous data of our lab, leptin levels were
significantly increased in LY female mice compared to age-matched controls at both 12
and 24 weeks of age.
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To determine potential mechanisms for obesity-induced cancer, HeLa cells were
treated with leptin in this study. Our data demonstrated that leptin increased the
expression of inflammation genes MCP-1 and IL-6 at 8 hours. It was reported previously
that leptin induced the expression of IL-6 and MCP-1 in obese mice and lean Wistar Rats
(22, 23). Our study similarly showed leptin-dependent increase in IL-6 and MCP-1
expression although the induction magnitude was not as great and likely reflects
differences between chronic and acute exposure to leptin. In addition,
advanced/metastatic cancer patients have higher levels of IL-6 in their blood (24). There
is an elevated levels of IL-6 in murine models of colitis-associated cancer (CAC) (25)
and the higher serum levels of IL-6 exhibited in males could be the reason of gender bias
in liver cancer susceptibility (26). IL-6 promotes the in vivo growth of tumors in models
of prostate, breast, and lung cancers (27). The increased IL-6 may be the important link
between increased leptin and obesity related cancer. In fact, obesity is associated with a
chronic inflammatory response characterized by over expressed cytokine such as IL-6 ,
TNF , inhibitor of NF- B kinase b (IKKb), macrophage migration inhibitory factor,
nerve growth factor, vascular endothelial growth factor, plasminogen activator inhibitor 1
and haptoglobin; increased acute-phase reactants, and activation of inflammatory
signaling pathways (28, 29).
Increased IL-6 and MCP-1 play very important roles in obese mice. Interestingly,
IL-6 has pro-inflammatory and anti-inflammatory function. IL-6 is secreted by immune
cells including T cells and macrophages in response to foreign pathogen stimulus, in
order to activate inflammation (22, 23). Thus, the increased leptin may play a role to
induce the micro-inflammatory condition in obesity. In fact, adipocytes are able to
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produce IL-6, as reported that endogenous CRP level is very high in obese individuals
(30). The inflammatory conditions in obesity may initiate or promote oncogenic
transformation, and also can generate an inflammatory microenvironment that promotes
tumor progression. MCP-1, is a small cytokine that functions as recruitment of
monocytes, memory T cells, and dendritic cells to sites of tissue injury, infection, and
inflammation. MCP-1 acts as chemotactic activity for monocytes and basophils but not
for neutrophils or eosinophils (31). Interestingly, many tumors are reported to produce
abundant MCP-1, including melanoma (32), ovarian cancer (33), and breast carcinoma
(34). Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.
In the current study, leptin did not affect FOS/JUN expression in 4 hours. While
in 8 hours, JUN mRNA appeared to be up-regulated. Jun, in combination with c-Fos, is
required for the increased activity at AP-1 promoters. AP-1 activity depends on both
double phosphorylations by the JNK pathway, and phosphorylation-independent
pathway. AP-1 proteins participate in tumorigenesis by regulating oncogenic
transformation, proliferation, apoptosis, invasive growth and angiogenesis (35). c-Jun
protein was established as an oncogene at the early stage of hepatocellular carcinoma in a
mouse mode (36). In mice with c-Jun deletion, the number and size of hepatic tumors
were reduced. This process was related to increased p53 level and apoptosis (36). In
mouse development and tumorigenesis model by Jochum’s, c-Jun binds to the promoter
of the P53 and cyclin D1, and then inhibit the p53 gene expression and stimulate the
cycline D1 gene expression (37). Inhibition of AP-1 activity by over-expressing a
dominant negative form of cJun (cjun-DN, Tam67) inhibits breast cancer cell growth.
Targeting the AP-1 transcription factor may be a key for the treatment of breast cancer
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(38, 39). Our data indicated leptin was able to increase JUN mRNA level in HeLa cells.
This suggests that JUN inhibition provides a promising therapeutic method for obesity
related cancer. However, we didn't find leptin was able to regulate the expression of
epithelial transition marker genes, including SNAI1/2, ZEB2, TWIST1, or JAG1 at early
hours in HeLa cells.
To seek for the early mediators which deliver leptin signaling, we demonstrated
that leptin was able to activate ERK1/2, JNK-STAT early at 15 minutes. Some studies
showed that leptin increased cancer cell growth through the ERK1/2 and JNK-STAT
pathway, increased cancer cell invasion via a PI-3K. In addition, the nuclear expressions
of ERK1/2 might be useful markers for tumor invasiveness and lymph node metastasis in
stomach cancer. Leptin promotes the growth of malignant cells by activating signal
transducer and activator of transcription 3 (STAT3) and kinase (ERK) 1/2 pathways in
breast cancer (46). ERK pathway is activated by a variety of stimuli including growth
factors, cytokines, virus infection, and carcinogens. It has been reported that leptin
markedly activated ERKs and JNK. In contrast, these stimulatory effects of leptin on
ERKs and JNK were completely inhibited by a PKC inhibitor Ro 32-0432 as well as
EDTA. In this process, Ca2+-independent novel PKC provides a link between leptin and
ERKs/JNK (47).These results provide an appropriate explanation on our finding.
ERKs pathway activates Fos and Jun, resulting in activation of AP-1. The
transcriptional activity of c-Fos is regulated by phosphorylation at Ser374 by ERK. JNK
also activates C-FOS via activation of ERK-1. JNK phosphorylates c-Jun at Ser63 and
Ser73(48, 49). STAT signaling is essential for the regulation of food intake and energy
expenditure by leptin. Binding of leptin to its receptor stimulates gene transcription via
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activation of STAT proteins. In Ishikawa cells, leptin was reported to increase STAT3DNA binding activity to Cyclin D1 promoter, enhance recruitment of STAT3 to the
promoter region of cyclin D1 (50). In contrast, STAT3 knockdown prevented leptininduced cyclin D1 expression and cell proliferation (50). Our data show the increased
phosphorylation of STAT3 though it is not significant. All of these data suggested a
strong link between leptin and tumor progression. However, the precise network between
leptin and ERK, JNK, and STAT pathway activation remain unclear. Further studies will
be needed to clarify these questions.
In summary, our data also indicated that both leptin and IL-6/MCP-1 activated
STAT3. Therefore, IL-6/MCP-1-STAT3 axis is a potential important pathway in obesitydependent cancers. In addition, there is an interest in developing anti-IL-6/MCP-1 agents
as therapy against obesity and cancers.
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Table 3.1. Human Primer sequences used for QPCR analysis

Gene

CASP10
FOS
JUN
MCP-1
IL-6
IL-8
SNAI1
SNAI2
TWIST1
ZEB2
JAG1
GAPDH

Probe
Dye
SYBR Green

Primer

Sequence (5' to 3')

Forward GGAGCTGTCTACTCTTCGGATGA
Reverse AGGGCTGTGAAGTGAGACATGAT
SYBR Green
Forward CCTCGCCCGGCTTTG
Reverse GCCTCGTAGTCTGCGTTGAAG
SYBR Green
Forward CTGGGAGGACCGGAGACA
Reverse GAGAAGCCTAAGACGCAGGAAA
SYBR Green
Forward CAAGCAGAAGTGGGTTCAGGAT
Reverse TCTTCGGAGTTTGGGTTTGC
Forward AGGGCTCTTCGGCAAATGTA
SYBR Green
Reverse GAAGGAATGCCCATTAACAACAA
Forward CTGGCCGTGGCTCTCTTG
SYBR Green
Reverse CCTTGGCAAAACTGCACCTT
Forward CCCCAATCGGAAGCCTAACT
SYBR Green
Reverse GCTGGAAGGTAAACTCTGGATTAGA
Forward CCTGGGCGCCCTGAA
SYBR Green
Reverse TTCTCCCCCGTGTGAGTTCT
Forward TCCGCGTCCCACTAGCA
SYBR Green
Reverse AGTTATCCAGCTCCAGAGTCTCTAGAC
Forward CCAGCTCGAGCGGCATA
SYBR Green
Reverse GCCACACTCTGTGCATTTGAA
Forward CAGCTCTGTGACAAAGATCTCAATTAC
SYBR Green
Reverse AGGGCCTGTGTTGCTACAAGTT
Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems
(VIC Probe)
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CHAPTER 4
Regulation of Immediate Early and EMT Markers Genes by Proinflammatory cytokines in HeLa Cells

ABSTRACT
Obesity is associated with a chronic inflammatory response characterized by overexpression of cytokines including TNFα and IL-6. Thus, there may be an important
relationship between abnormal chronic cytokine levels and cancer risk. To determine the
role of TNFα and IL-6 on the expression of genes associated with increased cancer risk in
obesity, HeLa cells were treated with IL-6 or TNFα for 0-8 hours. Quantitative, real-time
RT-PCR was carried out using primers against immediate early (IE) genes JUN, FOS, IL8, IL-6, MCP-1, and CASP10; and epithelial-mesenchymal transition (EMT) marker
genes SNAI1, SNAI2, Twist, JAG1, and ZEB2. IL-6 stimulated a significant transient
increase in FOS, IL-8 and MCP-1. Interestingly, IL-6 also increased the gene expression
of IL-6 in HeLa cells. Furthermore, SNAI1 mRNA abundance was significantly
increased by IL-6. Likewise TNFα treatment caused a transient increase in JUN, FOS,
IL-6 and IL-8. To assess more information of the activity of IL-6 and TNFα, Western blot
analyses were carried out to study phosphorylation of ERK1/2, STAT3, and SAPK/JNK.
Both IL-6 and TNF stimulated phosphorylation of SAPK/JNK ERK1/2 and STAT3. In
all, this study has identified a novel mechanism for important relationship between IL-6,
TNFα and cancer risk in obesity. It would be another key to provide new method to care
and prevent cancer.
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INTRODUCTION
Too much adipose tissue in obesity is not only characterized by increased
hormone level, but also with macrophage infiltration which are an important source of
inflammation in this tissue. In fact, obesity is associated with a chronic inflammatory
response characterized by over expressed cytokines such as IL-6 ,TNFα, inhibitor of NFB kinase b (IKKb), macrophage migration inhibitory factor, nerve growth factor,
vascular endothelial growth factor, plasminogen activator inhibitor 1 and haptoglobin;
increased acute-phase reactants, and activation of inflammatory signaling pathways (1, 2)
Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF ) are multifunctional
cytokines involved in the regulation of the immune response, hematopoiesis, and
inflammation. IL-6 is produced by numerous types of immune or immune accessory
cells, such as monocytes, fibroblasts, lymphocytes, and glial cells. It is also produced by
nonimmune cells such as adipose cells (5). Tumor necrosis factor alpha (TNF ) is a 26kDa transmembrane protein that is cleaved into a 17-kDa biologically active protein that
exerts its effects via type I and type II TNFα receptors. TNF is a member of a group of
cytokines involved in systemic inflammation and is a multifunctional cytokine playing a
role in apoptosis, cell survival, inflammation and immunity. TNF

plays an important

role in cancer, such as “cachectin” and T-lymphocyte differentiation factor (3, 4). In fact,
TNF also is able to inhibit tumorigenesis and viral replication.
At the beginning, IL-6 and TNFα were thought to be products of the immune
system alone that had immune functions only. Yet, it has become increasingly apparent
that the cytokines involving in both the nervous and endocrine systems. IL-6 and,TNFα
have been shown to have endocrine as well as autocrine and paracrine roles. IL-6 is a
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pleiotropic cytokine with many pathophysiologic roles in humans (6), which has drawn
much attention in the endocrine field including those studying the endocrine properties of
adipose tissue. Adipose tissue is recognized as endocrine organ to express and secrete a
variety of bioactive peptides, known as adipokines including IL-6, TNFα, adiponectin,
and leptin, which act at both the local (autocrine/paracrine) and systemic (endocrine)
level (1, 2, 7). In adipose tissue, TNFα is produced by adipocytes and stromovascular
cells (8). In fact, obesity is characterized chronic mild inflammation, with increased
circulating levels of inflammatory cytokine and the expression and release of
inflammation-related adipokines (1). Recently, it has been shown that IL-6 and TNFα are
both produced by the adipose tissue (5, 9), suggesting that they may play a key roles in
lipid metabolism.
Cytokines are known to have both tumor-promoting and inhibitory effects on
breast cancer growth depending presumably on their relative concentrations and the
presence of other modulating factors (10). These bioactive peptides produced the
adipose cell promote angiogenesis including vascular endothelial growth factor,
hepatocyte growth factor, leptin, tumour necrosis factor-alpha, heparin-binding epidermal
growth factor-like growth factor, and interleukin-6 (11). It is well known that there is an
increased cancer risk by obesity and there is growing evidence that tumors are sustained
and promoted by inflammatory signals from the surrounding microenvironment. Together
with the unbalance of hormones and factors which are produced by the adipose cells in
obesity, there may have a link between the adipose cells produced pro-inflammatory
cytokine and the increased risk of cancer. IL-6 and TNFα may play the key role in
increased cancer risk in obesity.

85
Interleukin-6 (IL-6) is a pleiotropic cytokine with obviously tumor-promoting and
tumor-inhibitory effects (10). Knüpfer has reported that, IL-6 would be a negative
prognosticator in breast tumor patients concerning patients‟ serum IL-6 levels (10).
Grivennikov and Bollrath demonstrated that the importance of the interleukin-6 family of
proinflammatory cytokines and their downstream effector STAT3 in colitis-associated
colon cancer (12, 13). Moreover, TNFα acts as a multifunctional cytokine to involve in
apoptosis, cell survival, inflammation, and immunity (14, 15). Recently, TNFα is used in
the regional treatment of locally advanced soft tissue sarcomas and metastatic melanomas
and other tumors (16).
In all, the pro-inflammatory cytokine IL-6 andTNFα would be a new key to
understand the link between obesity and cancer. We need to drew more attention to the
relationship between pro-inflammatory cytokine and cancer, such as IL-6 andTNFα in
obesity

MATERIALS AND METHODS

HeLa cell culture and whole cell protein extracts: 500,000 HeLa cells (American
Type Culture Collection, Manassas, VA) were cultured in 10 cm dish with Eagle‟s
Minimum Essential Medium pH 7.4 (Sigma, St. Louis, MO), containing 1.5 g/L
NaHCO3, 0.11 g/L Sodium pyruvate, 0.292 g/L L-glutamine, 10 ml/L Penn-strep, 1 ml/L
phenol red and 100 ml/L of heat inactivated FBS (Hyclone, Logan, UT, USA). After 24h,
the cells were changed to the same medium except there was no FBS included for serum
starvation. After 24h serum starvation, cells were treated with 10 ng/ml interleukin-6
(Cell Signaling Technology, Danvers, MA) or 10 ng/ml TNF

(Cell Signaling
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Technology, Danvers, MA) for 0, 15, 30 or 60 minutes. The cells were washed with 1X
HBSS (Invitrogen, Carlsbad, CA, USA) and cells collected in RIPA buffer (150 mM
NaCl, 1 mM EDTA, 50mM Tris-HCl pH7.4, 1% NP-40, 0.25% Na-deoxycholate)
containing phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4) and Complete Mini
Protease Inhibitor Cocktail (Roche Diagnostics). Cells in the RIPA buffer were sonicated
15 seconds and then centrifuged at 10,000 x g for 5 minute to separate cell debris and the
supernatant which contain soluble protein. The protein concentration of each
experimental replicate was determined with the Pierce BCA Protein Assay (Rockford, IL,
USA).
HeLa cell culture and RNA extraction: 200,000 HeLa cells (American Type
Culture Collection, Manassas, VA) were cultured in 3.5 cm dish and serum starved for 24
hours as described above. After serum starvation, cells were treated with 10 ng/ml IL-6 or
10 ng/ml TNF (Cell Signaling Technology) for 0, 0.25, 0.5, 1, 2, 4, or 8 hours. The cells
were washed with 1X HBSS (Invitrogen, Carlsbad, CA, USA) and then collected in TRI
reagent (Ambion Inc., Austin, TX, USA). Total RNA was extracted according to the
manufacturer‟s protocol (Sigma, St. Louis, MO). After isolation, the total RNA was
dissolved in 20 μl diethyl pyrocarbonate (DEPC) water. The RNA concentration was
determined using Beckman Coulter DU 730 Life Science UV/Vis Spectrophotometer.
Reverse Transcription: Total HeLa cell RNA (5 g) was mixed with 5 units of
RQ1 RNase free DNase (Promega, Madison, WI), M-MLV RT buffer and DEPC water
and incubated at 37°C for 30 minutes to remove genomic DNA contaminants. Before
RT-PCR, 1.1 μl of RNA and RQ1 mix was removed from each sample to a new tube with
15 μl DEPC water, which should be used as No RT to detect the residual genomic DNA.

87
The mixed RNA samples was subsequently combined with 2 μl Random primers
(Promega), 2 μl dexoxynucleotide triphosphates (Fermantas; 10 mM dNTP mix), 2.4 μl
DEPC water, and then were incubated in 65°C for 5 min. After that, the mixed samples
were chilled on the ice quickly. 400 units of Moloney Murine Leukemia Virus reverse
transcriptase (Promega), 3.2 μl of RT buffer (Invitrogen, Carlsbad, CA), and 2 μl 0.1 M
DL-dithiothreitol (DTT) (Invitrogen, Carlsbad, CA) were added into each sample. The
mixed samples were incubated at 37°C for 2 hour and followed by 15 min at 72°C to stop
the reverse transcriptase. The cDNA was stored at -20°C for subsequent real time-PCR.
Quantitative, Real-Time PCR (qPCR) Analysis: Gene-specific forward and
reverse primers were designed (Primer Express, Applied Biosystems, Foster City, CA)
and synthesized (Integrated DNA Technologies, Coralville, IA) and store at -20°C. The
information of the primers and probes are shown in table 4.1. Each set of gene-specific
primers was tested to determine the maximal concentration of primers that could be used
to produce specific amplification of the target sequence without primer dimer
amplification. Before use, each cDNA sample was diluted 1:10. Glyceradehyde-3phosphate dehydrogenase (Gapdh) gene is a housekeeping gene and used as a control for
reverse transcription efficiency and well-to-well variation in template. PCR was
performed with 10 μl Taqman Universal Master Mix (Applied Biosystem, Foster City,
CA), 1 μl cDNA, 1 μl probe with primers, and 8 μl DEPC to make up the reaction
volume to 20 μl. QRT-PCR was performed in 364 well plates (Axygen Scientific, Union
City, CA) with an adhesive cover film (VWR, Scientific Products, North Kansas City,
MO) in 7900HT Fast Real-Time PCR system (Applied Biosystems). Quantitative PCR
(qPCR) reactions of the other target genes were carried out using 1:10 dilutions of each
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cDNA sample and standard samples with Power SYBR Green PCR Master Mix (Applied
Biosystem, Foster City, CA). All experimental and Gapdh PCRs were carried out in
separate wells in triplicate. These relative values are plotted against the threshold value
for each dilution to generate a standard curve. An arbitrary value of template was
assigned to the highest standard and corresponding values were assigned to the
subsequent dilutions. According to the slope and y-intercept of the standard curve,
7900HT Fast Real-Time PCR system assigned a value of the relative amount for each
experimental and Gapdh triplicate. The value of the average of the experimental triplicate
divided by the average of the Gapdh triplicate was used for statistical analysis.
Western Blot Analyses: The protein samples were resolved by SDSpolyacrylamide 10% gel electrophoresis which contains 4% stacking gel and 10%
separating gel. Protein samples were loaded together with loading buffer and the
separated protein was transferred to Immobilon PVDF (Millipore, Billerica, MA).
Following transfer, the membranes were blocked with 5% nonfat dry milk in 1X TBST
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01% (v/v) Tween 20) for 1 hour with gentle
shaking in order to block the nonspecific proteins. After that, the blots were probed with
the primary antibodies which are diluted in 5% w/v BSA, 1XTBS, 0.1% Tween 20. The
membrane was then incubated with primary antibody against phospho-AKT (Cell
Signaling Technology, Danvers, MA), phospho-ERK1/2 (Cell Signaling Technology),
phospho-SAPK/JNK (Cell Signaling Technology), or phospho-STAT3 (Cell Signaling
Technology) overnight at 4°C with gentle shaking. Blots were washed with 1X TBST
and incubated for 1 hour with HRP-conjugated secondary antibody which was diluted
with 5% nonfat dry milk in 1X TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 01%
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(v/v) Tween 20). Proteins were incubated with West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL) for 5 min and exposed to autoradiograph film (Fisher Scientific,
Fairlawn, IL) in dark room. After the visualization of phosphorylated protein, the blots
were stripped with Restore plus Western Blot Stripping Buffer (Pierce) in room
temperature for 20 min and 37°C 10 min. Wash the blots with 1X TBST and blocked
with 5% milk in 1XTBST. Next, incubated with primary antibody against total AKT,
total ERK1/2, total SAPK/JNK, or total STAT3 (Cell Signaling Technology) overnight at
4°C with gentle shaking. Total protein was exposed and visualized as described above.
The visualized total protein served as a loading control for each sample. The
autoradiograph images films were scanned and the density of the protein band was
determined in Photoshop. Semi-quantitative analysis of band density of the
phosphorylated and total protein was calculated in each film as described by Miller
(http://lukemiller.org/journal/2007/08/quantifying-western-blots-without.html). The
amount of phosphorylated protein was normalized by total protein expressed in each
sample. The normalized abundance of phosphorylated protein of each sample was
subsequently compared to the untreated control sample. The data was showed as a foldchange.
Statistical Analyses: All statistical analyses were carried out by GraphPad Prism
4.0 (Graphpad Software, La Jolla, CA). QPCR data and western-blot data were analyzed
using one-way ANOVA. Differences in data were considered statistically significant at P
< 0.05. Different letters indicate significant differences in fold change in mRNA
abundance compared to control for all qPCR data and phospho-protein/total
protein ratio in time course. The Error bars represent mean ± SE.
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Results
Significant gene expression differences In HeLa cells by IL-6
To determine the effects of IL-6 on the regulation of immediate early genes, HeLa
cells were treated with 10ng/ml of IL-6 in a time course after 24h serum starvation. FOS,
IL-8 and MCP-1 have significant elevated mRNA expression level early in 1 hour, as
compared to untreated control cells. FOS mRNA increased by 2 fold, IL-8 by 7 fold, and
MCP-1 by 2 fold, respectively. After these peak increases in mRNA abundance, their
mRNA expression decreased quickly. Interestingly, IL-6 is able to induce its own mRNA
with an increase of 2 fold early at 0.5 hour. IL-6 mRNA induction arrived at peak at 1
hour, and dropped back to control level at 2 hours. However, IL-6 didn't lead to
significant induction on JUN and caspase 10 (Fig 4.1). The role of IL-6 on mRNA
induction of epithelial-mesenchymal transition marker genes was also assessed in the IL6 treated HeLa cells. SNAI1 mRNA was induced to 1.6 times control level. However,
IL-6 had no significant effect on mRNA level of SNAI2, ZEB2, TWIST1 and JAG1 (Fig
4.2).
Signaling Pathways regulated by IL-6 in HeLa cells
Here, we tested if 10ng/ml of IL-6 changes phosphorylation of ERK1/2 and JNKSTAT. Fig 4.3 showed that 10ng/ml IL-6 activated ERK1/2 by increasing
phosphorylation of ERK1/2 dependent of time. Early in 15 minutes, phosphorylation
of ERK1/2 increased by 4 fold in the induction of IL-6. In Fig 4.4, 10ng/ml IL-6
activated SAPK/JNK by increasing their phosphorylation by 2.5 fold in 15 minutes. But
phosphorylation of SAPK/JNK decreased quickly by 30 minutes post-treatment. In
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contrast, 10ng/ml IL-6 activated STAT3 by increasing its phosphorylation by 6 fold in 15
minutes and p-STAT-3 began to decrease after 30 minutes.
Significant gene expression differences In HeLa cells by TNFα
We also determined the effects of another important inflammation factor, TNFα,
on the regulation of immediate early genes. HeLa cells were treated with 10ng/ml of
TNFα in a time course after 24h serum starvation (Fig 4.5). JUN, FOS and IL-6 had
significant elevated mRNA expression level 30 minutes after treatment was initiated
compared to untreated control cells. JUN mRNA increased by 4-fold, FOS by 7-fold, and
IL-6 by 2-fold. TNF (10ng/ml) was also able to increase IL-8, MCP-1 mRNA at 1
hour. However, 10ng/ml of TNFα didn't lead to significant induction on pro-apoptotic
factor caspase 10. Fig 4.6 indicated that TNFα was also not able to lead to significant
induction of SNAI1, SNAI2, ZEB2, or TWIST1 mRNA, whereas JAG1 mRNA
expression was increased 2 hours post-treatment.
Signaling Pathways regulated byTNFα in HeLa cells
Here, we tested if 10ng/ml of TNFα changes phosphorylation of ERK1/2 and
JNK-STAT. Fig 4.7 showed that 10ng/mlTNFα activated ERK1/2 by increasing
phosphorylation of ERK dependent of time. Early in 15 minutes, phosphorylation
of ERK1/2 increased by 5.5 fold in the induction of TNFα. However, phosphorylation
of ERK1/2 got weaker and weaker after that. In Fig 4.7 and Fig 4.8, 10ng/ml TNFα
activated SAPK/JNK by increasing their phosphorylation by 7 fold in 15 minutes. But
phosphorylation of SAPK/JNK decreased quickly in another 15 minutes. In contrast,
10ng/mlTNFα activated STAT3 by increasing its phosphorylation by 1 fold in 15
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minutes. Interestingly, p-STAT-3 kept increasing. At 1 hour, p-STAT-3 increased by 3.5
fold.

Discussion
Inflammation is recognized to play important role in the pathogenesis of many
types of malignancies. Now, more and more attention has been focused on the role
cytokine of NF- B, IL-6, TNFα and their signal pathway in mediating the link between
inflammation and cancer. Michael Karin‟s group reported the elevated levels of IL-6 in
murine models of colitis-associatedcancer (CAC) (17). The higher serum levels of IL-6
exhibited in males could be the reason of gender bias in liver cancer susceptibility (18).
In our data, with the treatment of IL-6 in HeLa cell, there is a increased IL-6 mRNA
level. It seems as a positive feedback of IL-6 in inflammation. However, IL-6 promotes
the in vivo growth of tumors in models of prostate, breast, and lung cancers (10). The
increased IL-6 may be the important link between inflammation and cancer, which
promotes the tumorigenesis.
Our data also demonstrated that IL-6 is able to increase FOS mRNA level in 0.5
hour in HeLa cells. However, the JUN mRNA level was not induced significantly.
Therefore in our experiments, it is hard to evaluate the induction of AP-1 through IL-6
treatment. Apparently, as a pro-inflammatory factor, IL-6 is able to induce other
cytokines' transcription, including IL-8, MCP-1 in our data. IL-8 has been shown to
contribute to human cancer progression through its potential functions as a mitogenic,
angiogenic, and motogenic factor. IL-8 expression is regulated by various tumor
microenvironment factors, such as hypoxia, acidosis, nitric oxide, and cell density (19).
Le reported that IL-8 plays an important role in tumor angiogenesis and contributes
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significantly to the aggressive biology of human pancreatic cancer (20). Moreover,
point-mutation of NF- B, AP-1, or IL-6 binding sites significantly reduced or eliminated
the constitutive IL-8 promoter activity (20). As induced expression by IL-6 in HeLa cell,
the increased IL-8 may stimulate tumorigenesis. MCP-1 is a relevant negative regulator
of pancreatic cancer progression (21). All primary tumors were tested, and 6 of 14
pancreatic cancer cell lines were constitutively secreted MCP-1. The increased MCP-1 in
HeLa cell may be produced by the high activated HeLa cell or induced by proinflammatory cytokine which produced by HeLa cell or the treatment of IL-6.
IL-6 is an important cytokine, which acts as both a pro-inflammatory and antiinflammatory factor. IL-6-type cytokines bind to plasma membrane receptor complexes,
then induce transducing receptor chain gp 130 (glycoprotein 130), then activate the
associated Janus kinases (JAKs). STAT3 is a nuclear transcription factor downstream of
gp130. JAKs phosphorylate gp130, leading to the recruitment and activation of the
STAT3 and STAT1 transcription factors as well as other molecules (SHP2, Ras-MAPK,
and PI3K) (22). As Our western-blot data in HeLa cell, IL-6 activate phosphorylation of
ERK1/2, SAPK/JNK, and STAT3 early at 15 minutes, with continued increased
phosphorylation of STAT3 at 30min. As reported by Grivennikov and Bollrath, STAT is
necessary for the growth of colitis-associated colorectal cancer in mice (12, 23). STAT3
could induce and maintain a procarcinogenic inflammatory microenvironment, both at
the initiation of malignant transformation and during progression of cancer (12, 24, 25).
STAT3 is linked to inflammation associated tumorigenesis through genetic alterations in
malignant cells (26-28). In fact, STAT3 is frequently activated in malignant cells and
capable of inducing a large number of genes which are important for inflammation (29).
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In fact, STAT3 signalling is a major intrinsic pathway for cancer inflammation. IL-6 and
Stat3 are required for survival of intestinal epithelial cells and development of colitisassociated cancer. Take together, ERKs, JNK, STAT3 may be widely expressed protein
kinase intracellular signalling molecules that are involved in meiosis, mitosis.
It is reported that an inflammatory stimulus induces production of TNFα, and then
TNFα could primarily induce production of Il-1, IL-6, IL-8 and other pro-inflammatory
mediators (30, 31). In our experiment, we also used TNF alpha as the inducer in HeLa
cells. TNF alpha is able to lead to much stronger induction than did IL-6. In other words,
TNF alpha is sufficient to activate downstream genes in mRNA level. With TNFα
treatment, IL-6 had significant elevated mRNA expression level early in 0.5 hour, as
compared to control, while IL-8, MCP-1 mRNA with increase of 2 fold, 0.6 fold
respectively at 1 hour. The treatment of TNFα induces the production of IL-6, IL-8 and
MCP-1. The increased IL-6 and IL-8 may promote the tumorigensis as discuss above.
In addition, TNFα induce the increase of JUN mRNA by 4 fold, FOS by 7 fold in
HeLa cell. It is established that AP-1 proteins participate in tumorigenesis by regulating
oncogenic transformation, proliferation, apoptosis, invasive growth and angiogenesis. Fos
and FosB are dispensable for cell cycle progression, for example, fibroblasts and
embryonic stem cells have proliferation defect if lacking these components (32-34).
Moreover, over-expression of c-Fos induces cell death and resistant to apoptosis in an
embryonic Syrian hamster cell line (35). Over-expressed c-Fos transforms in
chondroblasts and osteoblasts, can induced the c-Fos-induced tumorigenesis (36, 37). In
fact, dependent on its ability to heterodimerize with Jun proteins and to bind to DNA, c-
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Fos acts as oncogenic. The dramatic induction of JUN and FOS mRNA level caused by
TNFα in HeLa cells may cause promotion of tumor.
However, TNFα is commonly used to treat cancer in clinical for it can be proangiogenic and used clinically to destroy tumor vasculature (38). Recently,TNFα is used
in cancer in the regional treatment of locally advanced soft tissue sarcomas and
metastatic melanomas and other tumors (16). TNFα is a potent anti-vascular cytokine at
higher doses. But TNF-α has powerful and toxic systemic side effects at the high dose
which limited uses in clinical (39). Paradoxically, TNFα is highly expresses in tumor and
recognized as pro-angiogenic with low dose (39). Although over the last few decades
high-dose administration of TNF-a has been used as a cytotoxic agent, recent pre-clinical
cancer models have support that chronic, low level TNF-a exposure cause the acquisition
of pro-malignant phenotype including increased growth, invasion and metastasis (40).
The growth of new capillaries into the tumor is called „tumorangiogenesis‟ (41, 42).
Angiogenesis is induced by the release of various proangiogenic cytokines by the tumor
cells and the supporting cells (43). Pro-angiogenic factors involve in endothelial cell
proliferation and migration, the formation of endothelial cells into new vasculature, and
the degradation of the basement membrane and the extracellular matrix (43), which are
important for the tumor growth. Low dose of TNFα works as pro-angiogenic factor and
may promote the tumorigenesis. The 10ng/ml TNFα in HeLa cell induce so many proinflammatory factor which may promote the tumorigenesis and the low dose may also
work as a pro-angiogenic factor and tumor-promoter to have positive function to tumor
growth.
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In the signal pathway,TNFα activated ERK1/2 by increasing phosphorylation
of ERK1/2 early at 15 minutes by 5.5 fold in the induction ofTNFα. While the
phosphorylation SAPK/JNK increase by 7 fold at 15 minutes. However, 10ng/mlTNFα
activated STAT3 by increasing its phosphorylation from 15 minutes to 1 hour. This
provides a clue that ERK and JNK-STAT are mediators to deliverTNFα signal to increase
some downstream target gene expression. Stat3 can be a link between inflammation and
cancer. STAT3 could induce and maintain a procarcinogenic inflammatory
microenvironment, both at the initiation of malignant transformation and during
progression of cancer (12, 24, 25). STAT3 is linked to inflammation associated
tumorigenesis through genetic alterations in malignant cells (26-28). In cancer cell,
Grivennikov and Bollrath demonstrate that STAT3 is necessary for the growth of colitisassociated colorectal cancer in mice (12, 23). It may provide another key to
understandTNFα as a pro-inflammation cytokine and its function in tumorigenesis.
In normal conditions, cytokines are known to have both tumor-promoting and
inhibitory effects on breast cancer growth depending presumably on their relative
concentrations with presence of other modulating factors (10). In fact, obesity is
associated with a chronic inflammatory response characterized by over expressed
cytokine such as IL-6 ,TNFα, adiponectin, inhibitor of NF-kB kinase b (IKKb),
macrophage migration inhibitory factor, nerve growth factor, vascular endothelial growth
factor, plasminogen activator inhibitor 1 and haptoglobin; increased acute-phase
reactants, and activation of inflammatory signaling pathways (1, 2). There is an increased
expression ofTNFα in adipose tissue in human obesity (44). The adipose cell produced
bioactive peptides including vascular endothelial growth factor, hepatocyte growth
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factor, leptin, tumor necrosis factor-alpha, heparin-binding epidermal growth factor-like
growth factor, and interleukin-6 (11). The inflammatory conditions in obesity may
initiate or promote oncogenic transformation, and also can generate an inflammatory
microenvironment that promotes tumour progression. Take together, the effects and
function of the elevations of the cytokines in obesity may be a link to understand more
about the obesity related cancer. To understand the important roles of TNF-a and IL-6 in
the process of tumor promotion will assist in the development of cancer therapeutics.
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Table 4.1. Human Primer sequences used for QPCR analysis
Gene

Probe
Dye

CASP10

SYBR Green

FOS
JUN
MCP-1
IL-6
IL-8
SNAI1
SNAI2
TWIST1
ZEB2
JAG1
GAPDH

Primer

Sequence (5' to 3')

Forward GGAGCTGTCTACTCTTCGGATGA
Reverse AGGGCTGTGAAGTGAGACATGAT
SYBR Green
Forward CCTCGCCCGGCTTTG
Reverse GCCTCGTAGTCTGCGTTGAAG
SYBR Green
Forward CTGGGAGGACCGGAGACA
Reverse GAGAAGCCTAAGACGCAGGAAA
SYBR Green
Forward CAAGCAGAAGTGGGTTCAGGAT
Reverse TCTTCGGAGTTTGGGTTTGC
Forward AGGGCTCTTCGGCAAATGTA
SYBR Green
Reverse GAAGGAATGCCCATTAACAACAA
Forward CTGGCCGTGGCTCTCTTG
SYBR Green
Reverse CCTTGGCAAAACTGCACCTT
Forward CCCCAATCGGAAGCCTAACT
SYBR Green
Reverse GCTGGAAGGTAAACTCTGGATTAGA
Forward CCTGGGCGCCCTGAA
SYBR Green
Reverse TTCTCCCCCGTGTGAGTTCT
Forward TCCGCGTCCCACTAGCA
SYBR Green
Reverse AGTTATCCAGCTCCAGAGTCTCTAGAC
Forward CCAGCTCGAGCGGCATA
SYBR Green
Reverse GCCACACTCTGTGCATTTGAA
Forward CAGCTCTGTGACAAAGATCTCAATTAC
SYBR Green
Reverse AGGGCCTGTGTTGCTACAAGTT
Kit-Taqman Rodent GapDH Control Reagents Applied Biosystems
(VIC Probe)
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CHAPTER 5
Summary

In this thesis, we have demonstrated that the abnormal adipocytekines play an important
role in obesity associated increased cancer risk in obesity. We believe that the data in this thesis
support our hypothesis that Obesity-associated adipocytokines regulate IE, and EMT genes
expression profile of HeLa cells and in uterus of LY mouse.
IGF-1 activates signaling pathways of AKT, Erk1/2, STAT3 and SAPK/JNK and then
regulates IE and EMT genes. Activated PI3/AKT by IGF-1 can stimulate c-Jun N-terminal
kinase (JNK) and then stimulates AP-1 transcription. In addition, leptin activates signaling
pathways of STAT3 and SAPK/JNK and then regulate of IE genes. However, IL-6 and TNFα
can both activate signaling pathways of Erk1/2, STAT3 and SAPK/JNK and then regulate of IE
and EMT genes. The activated pStat3 by IGF-1, or leptin, or IL-6 or TNFα, enhance SIS-induced
enhancer of AP-1 transcription. Activation of ERK2 can cause the activation of MAPK pathway
and then increase AP-1 transcription. In addition, phosphorylation of SAPK/JNK by the
adipocytokines stimulates AP-1 transcription. AP-1 transcription factors enhance the induced
EMT by IGF-1, or leptin, or IL-6 or TNFα. In all, the increased IE may increase the cell survival
and promote tumorigensis. The activation of EMT also protects from cell death and promotes
tumorigensis. Moreover, the increased pro-inflammatory cytokines including IL-6, IL-8, MCP-1
may cause inflammatory environment in obesity. The inflammatory environments may initiate or
promote oncogenic transformation. All the relationships are showed in the figure 6.1.
Taken together, there is a link between adipocytokine and the expression of genes
associated with cell proliferation and migration. The adipocytokine plays an important role in the
initiation and metastasis of tumors in obesity. These changes in gene expression may provide a
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plausible mechanism for obesity-dependent increases risk in cancers of the female reproductive
tract.

Figure 5.1. Experimental working model. The relationship between the four
adipocytokins and obesity associated cancer in my experiments.

